| Year |
Citation |
Score |
| 2024 |
van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, Shi Y, Mansilla-Soto J, Hamieh M, Eyquem J, Cabriolu A, Wang X, Abujarour R, Lee T, Clarke R, ... ... Sadelain M, et al. Author Correction: Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering. PMID 38347164 DOI: 10.1038/s41551-024-01181-y |
0.383 |
|
| 2024 |
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, ... ... Sadelain M, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nature Aging. PMID 38267706 DOI: 10.1038/s43587-023-00560-5 |
0.336 |
|
| 2023 |
Jain N, Zhao Z, Koche RP, Antelope C, Gozlan Y, Montalbano A, Brocks D, Lopez M, Dobrin A, Shi Y, Gunset G, Giavridis T, Sadelain M. Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function. Cancer Discovery. PMID 37934007 DOI: 10.1158/2159-8290.CD-22-1319 |
0.426 |
|
| 2023 |
Hammer Q, Perica K, van Ooijen H, Mbofung R, Momayyezi P, Varady E, Martin KE, Pan Y, Jelcic M, Groff B, Abujarour R, Krokeide S, Lee T, Williams A, Goodridge JP, ... ... Sadelain M, et al. Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells. Biorxiv : the Preprint Server For Biology. PMID 37873468 DOI: 10.1101/2023.10.09.557143 |
0.372 |
|
| 2023 |
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, ... ... Sadelain M, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Research Square. PMID 37841853 DOI: 10.21203/rs.3.rs-3385749/v1 |
0.343 |
|
| 2023 |
Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, Lopez M, Ng MR, Fraser K, Subklewe M, Park JH, Wang X, Rivière I, Sadelain M. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 41: 1871-1891.e6. PMID 37802054 DOI: 10.1016/j.ccell.2023.09.010 |
0.341 |
|
| 2023 |
Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, ... ... Sadelain M, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nature Medicine. PMID 37400640 DOI: 10.1038/s41591-023-02404-6 |
0.358 |
|
| 2023 |
Hamieh M, Mansilla-Soto J, Rivière I, Sadelain M. Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. Cancer Discovery. 13: 829-843. PMID 36961206 DOI: 10.1158/2159-8290.CD-23-0101 |
0.33 |
|
| 2023 |
He C, Mansilla-Soto J, Khanra N, Hamieh M, Bustos V, Paquette AJ, Garcia Angus A, Shore DM, Rice WJ, Khelashvili G, Sadelain M, Meyerson JR. CD19 CAR antigen engagement mechanisms and affinity tuning. Science Immunology. 8: eadf1426. PMID 36867678 DOI: 10.1126/sciimmunol.adf1426 |
0.432 |
|
| 2023 |
Sjöstrand M, Sadelain M. Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma. Haematologica. PMID 36794501 DOI: 10.3324/haematol.2022.282053 |
0.311 |
|
| 2023 |
Jain N, Zhao Z, Feucht J, Koche R, Iyer A, Dobrin A, Mansilla-Soto J, Yang J, Zhan Y, Lopez M, Gunset G, Sadelain M. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature. PMID 36755094 DOI: 10.1038/s41586-022-05692-z |
0.397 |
|
| 2023 |
Odak A, Yuan H, Feucht J, Cantu VA, Mansilla-Soto J, Kogel F, Eyquem J, Everett JK, Bushman FD, Leslie C, Sadelain M. Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. Blood. PMID 36745870 DOI: 10.1182/blood.2022018924 |
0.425 |
|
| 2022 |
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, ... ... Sadelain M, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8 T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 56: 93-106.e6. PMID 36574773 DOI: 10.1016/j.immuni.2022.12.001 |
0.304 |
|
| 2022 |
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, ... ... Sadelain M, et al. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. PMID 36253610 DOI: 10.1038/s41591-022-02069-7 |
0.305 |
|
| 2022 |
Qualls D, Monette S, Sethi S, Dogan A, Roshal M, Senechal B, Wang X, Riviere I, Sadelain M, Brentjens R, Park J, Smith E, Palomba ML. CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials. Clinical Lymphoma, Myeloma & Leukemia. S443. PMID 36164217 DOI: 10.1016/S2152-2650(22)01664-0 |
0.331 |
|
| 2022 |
van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, Shi Y, Mansilla-Soto J, Hamieh M, Eyquem J, Cabriolu A, Wang X, Abujarour R, Lee T, Clarke R, ... ... Sadelain M, et al. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering. PMID 35941192 DOI: 10.1038/s41551-022-00915-0 |
0.419 |
|
| 2022 |
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, ... ... Sadelain M, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. PMID 35288695 DOI: 10.1038/s41591-022-01702-9 |
0.351 |
|
| 2022 |
Palomba ML, Qualls D, Monette S, Sethi S, Dogan A, Roshal M, Senechal B, Wang X, Rivière I, Sadelain M, Brentjens RJ, Park JH, Smith EL. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. Journal For Immunotherapy of Cancer. 10. PMID 35173030 DOI: 10.1136/jitc-2021-004128 |
0.375 |
|
| 2022 |
Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjöstrand M, Lindenbergh PL, Saetersmoen M, Dobrin A, Maurin M, Iyer A, Garcia Angus A, ... ... Sadelain M, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nature Medicine. PMID 35027758 DOI: 10.1038/s41591-021-01621-1 |
0.371 |
|
| 2022 |
Boulad F, Maggio A, Wang X, Moi P, Acuto S, Kogel F, Takpradit C, Prockop S, Mansilla-Soto J, Cabriolu A, Odak A, Qu J, Thummar K, Du F, Shen L, ... ... Sadelain M, et al. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial. Nature Medicine. PMID 34980909 DOI: 10.1038/s41591-021-01554-9 |
0.324 |
|
| 2021 |
Jing R, Jiao P, Chen J, Meng X, Wu X, Duan Y, Shang K, Qian L, Huang Y, Liu J, Huang T, Jin J, Chen W, Zeng X, Yin W, ... ... Sadelain M, et al. Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells. Small Methods. 5: e2100071. PMID 34927998 DOI: 10.1002/smtd.202100071 |
0.395 |
|
| 2021 |
Adusumilli PS, Zauderer MG, Riviere I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, Pineda J, Perez-Johnston R, Tan KS, Daly B, Araujo Filho JA, ... ... Sadelain M, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discovery. PMID 34266984 DOI: 10.1158/2159-8290.CD-21-0407 |
0.354 |
|
| 2021 |
Levin AG, Rivière I, Eshhar Z, Sadelain M. CAR T cells: building on the CD19 paradigm. European Journal of Immunology. PMID 34196410 DOI: 10.1002/eji.202049064 |
0.454 |
|
| 2021 |
Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews. Immunology. PMID 34002066 DOI: 10.1038/s41577-021-00547-6 |
0.322 |
|
| 2021 |
Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, et al. Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy. Blood. PMID 33851211 DOI: 10.1182/blood.2020009515 |
0.363 |
|
| 2020 |
Stone EF, Avecilla ST, Wuest DL, Lomas-Francis C, Westhoff CM, Diuguid DL, Sadelain M, Boulad F, Shi PA. Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy. Haematologica. PMID 32817291 DOI: 10.3324/Haematol.2020.253229 |
0.424 |
|
| 2020 |
Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, ... ... Sadelain M, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. PMID 32555459 DOI: 10.1038/S41586-020-2403-9 |
0.458 |
|
| 2020 |
Imber BS, Sadelain M, DeSelm C, Batlevi C, Brentjens RJ, Dahi PB, Giralt S, Park JH, Sauter C, Scordo M, Shah G, Perales MA, Palomba ML, Yahalom J. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. British Journal of Haematology. PMID 32135029 DOI: 10.1111/Bjh.16541 |
0.41 |
|
| 2020 |
Mandal M, Clarke R, Stegen Svd, Chang C, Lai Y, Witty A, Husain M, Wu C, Yang B, Dufaud C, Hsia G, Shaked H, Stokely L, Chu H, Pribadi M, ... ... Sadelain M, et al. Abstract 3245: FT819 path to IND: First-of-kind off-the-shelf CAR19 T-cell for B cell malignancies Immunology. DOI: 10.1158/1538-7445.Am2020-3245 |
0.459 |
|
| 2020 |
Curran KJ, Sauter CS, Kernan NA, Prockop SE, Boulad F, Perales M, Giralt SA, Riviere I, Wang X, Boelens J, Sadelain M, Brentjens R, O'Reilly RJ. Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies Biology of Blood and Marrow Transplantation. 26: S89. DOI: 10.1016/J.Bbmt.2019.12.590 |
0.539 |
|
| 2019 |
Curran KJ, Margossian S, Kernan NA, Silverman LB, Williams DA, Shukla NN, Kobos R, Forlenza C, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, ... ... Sadelain M, et al. Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. Blood. PMID 31650176 DOI: 10.1182/Blood.2019001641 |
0.616 |
|
| 2019 |
Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine. 11. PMID 31270272 DOI: 10.1126/Scitranslmed.Aau5907 |
0.491 |
|
| 2019 |
Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, ... ... Sadelain M, et al. CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma. Blood. PMID 31262783 DOI: 10.1182/Blood.2018883421 |
0.47 |
|
| 2019 |
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, ... ... Sadelain M, et al. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation. PMID 31092900 DOI: 10.1038/S41409-019-0451-2 |
0.458 |
|
| 2019 |
Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J, Sadelain M, Lokhorst HM, Groen R, Mutis T, Themeli M. Combined CD28 and 4-1BB costimulation potentiates affinity-tuned Chimeric Antigen Receptor-engineered T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30979735 DOI: 10.1158/1078-0432.Ccr-18-2559 |
0.471 |
|
| 2019 |
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, Sadelain M, Park JH, Brentjens RJ. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. Jci Insight. 5. PMID 30938714 DOI: 10.1172/Jci.Insight.122627 |
0.422 |
|
| 2019 |
Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, Li Z, Cunanan KM, Huse M, Hendrickson RC, Wang X, ... ... Sadelain M, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. PMID 30918399 DOI: 10.1038/S41586-019-1054-1 |
0.506 |
|
| 2019 |
Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine. PMID 30692700 DOI: 10.1038/S41591-019-0360-3 |
0.4 |
|
| 2019 |
Perica K, Flynn J, Curran KJ, Wang X, Halton E, Diamonte C, Pineda J, Bernal Y, Gonen M, Riviere I, Sadelain M, Brentjens RJ, Park JH. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. Journal of Clinical Oncology. 37: 2520-2520. DOI: 10.1200/Jco.2019.37.15_Suppl.2520 |
0.441 |
|
| 2019 |
Adusumilli PS, Zauderer MG, Rusch VW, O'Cearbhaill R, Zhu A, Ngai D, McGee E, Chintala N, Messinger J, Cheema W, Halton E, Diamonte C, Pineda J, Vincent A, Modi S, ... ... Sadelain M, et al. Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. Journal of Clinical Oncology. 37: 2511-2511. DOI: 10.1200/Jco.2019.37.15_Suppl.2511 |
0.457 |
|
| 2019 |
Imber B, Palomba ML, DeSelm C, Batlevi CL, Dahi PB, Giralt SA, Noy A, Park JH, Sauter CS, Scordo M, Shah GL, Sadelain M, Perales M, Yahalom J. MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy Blood. 134: 3238-3238. DOI: 10.1182/Blood-2019-131449 |
0.342 |
|
| 2019 |
Chang C, Van Der Stegen S, Mili M, Clarke R, Lai Y, Witty A, Lindenbergh P, Yang B, Husain M, Shaked H, Groff B, Stokely L, Abujarour R, Lee T, Chu H, ... ... Sadelain M, et al. FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial Blood. 134: 4434-4434. DOI: 10.1182/Blood-2019-130584 |
0.548 |
|
| 2019 |
Imber B, Palomba ML, DeSelm C, Dahi PB, Sauter CS, Scordo M, Batlevi CL, Park JH, Shah GL, Giralt SA, Perales M, Sadelain M, Yahalom J. Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy Blood. 134: 3244-3244. DOI: 10.1182/Blood-2019-129620 |
0.386 |
|
| 2019 |
Park JH, Flynn J, Gonen M, Bernal Y, Diamonte C, Halton E, Wang X, Riviere I, Sadelain M, Brentjens RJ. Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL Blood. 134: 1348-1348. DOI: 10.1182/Blood-2019-129343 |
0.397 |
|
| 2019 |
Abujarour R, Lai Y, Pribadi M, Lee T, Robinson M, Ruller C, Stegen SVd, Wang X, Stefanski J, Zhen J, Dinella J, Bonello G, Huffman J, Chu H, Clarke R, ... ... Sadelain M, et al. Abstract LB-073: Generation of novel single cell-derived engineered master pluripotent cell line as a renewable source for off-the-shelf TCR-less CAR T cells in support of first-of-kind clinical trial Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-073 |
0.531 |
|
| 2019 |
Adusumilli PS, Zauderer MG, Rusch VW, O'Cearbhaill RE, Zhu A, Ngai DA, McGee E, Chintala NK, Messinger JC, Vincent A, Halton EF, Diamonte C, Pineda J, Modi S, Solomon SB, ... ... Sadelain M, et al. Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct036 |
0.479 |
|
| 2019 |
Palomba ML, Batlevi C, Riviere I, Senechal B, Wang X, Yang J, Kane P, Bernal Y, Furman RR, Diamonte C, Halton E, Pineda J, Renier B, Sadelain M, Jae P. A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION Hemasphere. 3: 755. DOI: 10.1097/01.hs9.0000564784.30358.fe |
0.311 |
|
| 2019 |
Capelletti M, Liegel J, Themeli M, Mutis T, Stroopinsky D, Orr S, Torres D, Morin A, Gunset G, Ghiasuddin H, Rahimian M, Nahas M, Bisharat L, Meng S, Munshi NC, ... ... Sadelain M, et al. Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies Blood. 134: 3227-3227. DOI: 10.1016/J.Bbmt.2019.12.110 |
0.484 |
|
| 2019 |
Curran KJ, Margossian S, Kernan NA, Boulad F, Cancio M, Prockop SE, Scaradavou A, Spitzer B, Szenes V, Riviere I, Sadelain M, Boelens J, O'Reilly RJ, Brentjens R. Conditioning Prior to CAR T Cells Predicts Response and Survival in Pediatric/Young Adult Relapse/Refractory (R/R) B-ALL Biology of Blood and Marrow Transplantation. 25: S170. DOI: 10.1016/J.Bbmt.2018.12.309 |
0.555 |
|
| 2019 |
Batlevi C, Palomba M, Park J, Mead E, Santomasso B, Riviere I, Wang X, Senechal B, Furman R, Yang J, Kane P, Hall M, Bernal Y, Lund N, Diamonte C, ... ... Sadelain M, et al. PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION Hematological Oncology. 37: 166-167. DOI: 10.1002/Hon.124_2629 |
0.413 |
|
| 2018 |
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, ... ... Sadelain M, et al. Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30576834 DOI: 10.1016/J.Bbmt.2018.12.068 |
0.458 |
|
| 2018 |
Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine. PMID 30559421 DOI: 10.1038/S41591-018-0290-5 |
0.499 |
|
| 2018 |
DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, Sadelain M. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. Molecular Therapy : the Journal of the American Society of Gene Therapy. 26: 2542-2552. PMID 30415658 DOI: 10.1016/J.Ymthe.2018.09.008 |
0.425 |
|
| 2018 |
Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, ... ... Sadelain M, et al. Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular Therapy. Methods & Clinical Development. 10: 371-378. PMID 30211249 DOI: 10.1016/J.Omtm.2018.08.006 |
0.382 |
|
| 2018 |
Hamieh M, Sadelain M. Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia. Trends in Molecular Medicine. 24: 729-731. PMID 30149852 DOI: 10.1016/J.Molmed.2018.06.007 |
0.448 |
|
| 2018 |
June CH, Sadelain M. Chimeric Antigen Receptor Therapy. The New England Journal of Medicine. 379: 64-73. PMID 29972754 DOI: 10.1056/Nejmra1706169 |
0.453 |
|
| 2018 |
Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, ... ... Sadelain M, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. PMID 29946192 DOI: 10.1038/S41375-018-0180-3 |
0.413 |
|
| 2018 |
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29910179 DOI: 10.1016/J.Ymthe.2018.05.018 |
0.49 |
|
| 2018 |
Krebs S, Ahad A, Carter L, Eyquem J, Brand C, Bell M, Ponomarev V, Reiner T, Meares CF, Gottschalk S, Sadelain M, Larson SM, Weber WA. Antibody with infinite affinity for in vivo tracking of genetically engineered lymphocytes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29903928 DOI: 10.2967/Jnumed.118.208041 |
0.515 |
|
| 2018 |
Santomasso BD, Park JH, Salloum D, Rivière I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, ... ... Sadelain M, et al. Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL). Cancer Discovery. PMID 29880584 DOI: 10.1158/2159-8290.Cd-17-1319 |
0.453 |
|
| 2018 |
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature Medicine. 24: 731-738. PMID 29808005 DOI: 10.1038/S41591-018-0041-7 |
0.443 |
|
| 2018 |
Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK. Cytokine Release Syndrome Grade is a Predictive Marker for Infections in Relapsed or Refractory B-cell All Patients Treated with CAR T Cells. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29481659 DOI: 10.1093/Cid/Ciy152 |
0.478 |
|
| 2018 |
Boulad F, Mansilla-Soto J, Cabriolu A, Rivière I, Sadelain M. Gene Therapy and Genome Editing. Hematology/Oncology Clinics of North America. 32: 329-342. PMID 29458735 DOI: 10.1016/J.Hoc.2017.11.007 |
0.368 |
|
| 2018 |
Perales MA, Kebriaei P, Kean LS, Sadelain M. Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 24: S15-S19. PMID 29425516 DOI: 10.1016/J.Bbmt.2017.12.789 |
0.476 |
|
| 2018 |
Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Wiener Fedus S, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. PMID 29419425 DOI: 10.3324/Haematol.2017.187047 |
0.404 |
|
| 2018 |
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. The New England Journal of Medicine. 378: 449-459. PMID 29385376 DOI: 10.1056/Nejmoa1709919 |
0.378 |
|
| 2018 |
Smith M, Zakrzewski J, James S, Sadelain M. Posttransplant chimeric antigen receptor therapy. Blood. PMID 29358181 DOI: 10.1182/Blood-2017-08-752121 |
0.547 |
|
| 2018 |
Pan Y, Yoon S, Sun J, Huang Z, Lee C, Allen M, Wu Y, Chang YJ, Sadelain M, Shung KK, Chien S, Wang Y. Mechanogenetics for the remote and noninvasive control of cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29343642 DOI: 10.1073/Pnas.1714900115 |
0.488 |
|
| 2018 |
Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science (New York, N.Y.). 359. PMID 29326244 DOI: 10.1126/Science.Aan4672 |
0.4 |
|
| 2018 |
Park JH, Palomba ML, Batlevi CL, Riviere I, Wang X, Senechal B, Furman RR, Bernal Y, Hall M, Pineda J, Diamonte C, Halton E, Brentjens RJ, Sadelain M. A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation Blood. 132: 224-224. DOI: 10.1182/Blood-2018-99-117737 |
0.434 |
|
| 2018 |
Feucht J, Sun J, Eyquem J, Ho Y, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M. Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency Blood. 132: 1412-1412. DOI: 10.1182/Blood-2018-99-117698 |
0.529 |
|
| 2018 |
Clarke R, Van Der Stegen S, Chang C, Husain M, Lai Y, Peralta E, Stokely L, Abujarour R, Dinella J, Lee T, Pribadi M, Chu H, Truong C, Sabouri-Ghomi M, Meza M, ... ... Sadelain M, et al. Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies Blood. 132: 4546-4546. DOI: 10.1182/Blood-2018-99-116843 |
0.543 |
|
| 2018 |
Clarke RL, Stegen Svd, Lee T, Mansilla-Soto J, Chang C, Sasaki J, Husain M, Peralta E, Hardy I, Ortiz E, Riviere I, Sadelain M, Valamehr B. Abstract LB-108: Generation of off-the-shelf TCR-less CAR-targeted cytotoxic T cells from renewable pluripotent cells for cancer immunotherapy Immunology. 78. DOI: 10.1158/1538-7445.Am2018-Lb-108 |
0.559 |
|
| 2018 |
Giavridis T, Stegen SJvd, Eyquem J, Hamieh M, Sadelain M. Abstract 2567: Novel therapeutic interventions to alleviate CAR T cell-induced cytokine release syndrome Cancer Research. 78: 2567-2567. DOI: 10.1158/1538-7445.Am2018-2567 |
0.457 |
|
| 2018 |
Lis R, Mansilla-Soto J, Duran JGB, Lu T, Sadelain M, Rafii S. Engineering Converted Autologous Hematopoietic Stem Cells From Vascular Endothelial for Treatment of Hemoglobinopathies Experimental Hematology. 64: S46. DOI: 10.1016/J.Exphem.2018.06.055 |
0.312 |
|
| 2017 |
Sadelain M. CD19 CAR T Cells. Cell. 171: 1471. PMID 29245005 DOI: 10.1016/J.Cell.2017.12.002 |
0.52 |
|
| 2017 |
Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. Leukemia & Lymphoma. 1-5. PMID 29043880 DOI: 10.1080/10428194.2017.1390237 |
0.405 |
|
| 2017 |
Perales MA, Kebriaei P, Kean LS, Sadelain M. Building a Safer and Faster CAR: Seatbelts, Airbags and Crispr. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29032264 DOI: 10.1016/J.Bbmt.2017.10.017 |
0.479 |
|
| 2017 |
Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, Hendrickson RC, Brennan CW, Sadelain M. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. Cancer Cell. 32: 506-519.e5. PMID 29017060 DOI: 10.1016/J.Ccell.2017.09.004 |
0.441 |
|
| 2017 |
Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 545: 423-431. PMID 28541315 DOI: 10.1038/Nature22395 |
0.503 |
|
| 2017 |
Rivière I, Sadelain M. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28456379 DOI: 10.1016/J.Ymthe.2017.03.034 |
0.487 |
|
| 2017 |
Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. PMID 28225754 DOI: 10.1038/Nature21405 |
0.554 |
|
| 2017 |
Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, ... ... Sadelain M, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nature Medicine. PMID 28067900 DOI: 10.1038/Nm.4258 |
0.527 |
|
| 2017 |
Park JH, Riviere I, Wang X, Senechal B, Bernal Y, Halton E, Diamonte C, Wang Y, Brentjens RJ, Sadelain M. A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology. 35: TPS7568-TPS7568. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps7568 |
0.516 |
|
| 2017 |
Park JH, Santomasso B, Riviere I, Senechal B, Wang X, Purdon T, Wang Y, Halton E, Diamonte C, Li D, Sadelain M, Brentjens RJ. Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL. Journal of Clinical Oncology. 35: 7024-7024. DOI: 10.1200/Jco.2017.35.15_Suppl.7024 |
0.419 |
|
| 2017 |
Park JH, Riviere I, Wang X, Senechal B, Wang Y, Mead E, Santomasso B, Halton E, Diamonte C, Bernal Y, Li D, Sadelain M, Brentjens RJ. Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy. Journal of Clinical Oncology. 35: 7008-7008. DOI: 10.1200/Jco.2017.35.15_Suppl.7008 |
0.452 |
|
| 2017 |
Santomasso B, Park JH, Riviere I, Mead E, Halton E, Diamonte C, Purdon T, Senechal B, Li D, Sadelain M, Brentjens RJ. Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells. Journal of Clinical Oncology. 35: 3019-3019. DOI: 10.1200/Jco.2017.35.15_Suppl.3019 |
0.398 |
|
| 2017 |
Stegen SVD, Clarke R, Soto JM, Ortiz E, Chang C, Sasaki J, Lee T, Lan W, Shoemaker D, Riviere I, Valamehr B, Sadelain M. Generation of Clonal Antigen Specific CD8αβ+ Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics Blood. 130: 163-163. DOI: 10.1182/Blood.V130.Suppl_1.163.163 |
0.544 |
|
| 2017 |
Curran KJ, Margossian SP, Kernan NA, Silverman LB, Park JH, Sauter CS, Smith EL, Boulad F, Cancio MI, Forlenza C, Jackson C, Shukla N, Spitzer B, Prockop S, Steinherz PG, ... ... Sadelain M, et al. High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL Blood. 130: 1326-1326. DOI: 10.1182/Blood.V130.Suppl_1.1326.1326 |
0.561 |
|
| 2017 |
Sadelain M, Eyquem J. Abstract IA22: Targeting CARs to the TRAC locus enhances T-cell potency Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Ia22 |
0.553 |
|
| 2017 |
Park JH, Rivere I, Wang X, Senechal B, Curran K, Sauter C, Wang Y, Santomasso B, Li D, Brentjens R, Sadelain M. Abstract CT078: Impact of disease burden and transplant on long-term survival after CD19 CAR therapy in adults with relapsed B-cell acute lymphoblastic leukemia Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct078 |
0.463 |
|
| 2017 |
Morello A, Chen N, Cherkassky L, Sadelain M, Jones D, Adusumilli P. OA02.06 Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation to Potentiate Thoracic Cancers Immunotherapy Journal of Thoracic Oncology. 12: S249. DOI: 10.1016/J.Jtho.2016.11.236 |
0.345 |
|
| 2017 |
Sauter C, Riviere I, Senechal B, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Moskowitz C, Giralt S, Matasar M, Curran K, Park J, Sadelain M, Brentjens R. A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) Hematological Oncology. 35: 138-139. DOI: 10.1002/Hon.2437_128 |
0.376 |
|
| 2016 |
Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Molecular Therapy Oncolytics. 3: 1-9. PMID 29675462 DOI: 10.1038/Mto.2016.23 |
0.43 |
|
| 2016 |
Perna F, Sadelain M. Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. Translational Cancer Research. 5: S221-S225. PMID 28824851 DOI: 10.21037/Tcr.2016.08.15 |
0.341 |
|
| 2016 |
Kotini AG, Sadelain M, Papapetrou EP. LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy. Nucleic Acids. 5: e394. PMID 28427140 DOI: 10.1038/mtna.2016.99 |
0.612 |
|
| 2016 |
Kotini AG, Sadelain M, Papapetrou EP. LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy. Nucleic Acids. 5: e394. PMID 28131289 DOI: 10.1038/mtna.2016.99 |
0.612 |
|
| 2016 |
Kotini AG, Sadelain M, Papapetrou EP. LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy. Nucleic Acids. 5: e394. PMID 27898090 DOI: 10.1038/Mtna.2016.99 |
0.648 |
|
| 2016 |
Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. The Journal of Clinical Investigation. PMID 27760047 DOI: 10.1172/Jci84813 |
0.537 |
|
| 2016 |
Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. The Journal of Clinical Investigation. PMID 27454297 DOI: 10.1172/Jci83092 |
0.45 |
|
| 2016 |
Sadelain M. Chimeric antigen receptors: driving immunology towards synthetic biology. Current Opinion in Immunology. 41: 68-76. PMID 27372731 DOI: 10.1016/J.Coi.2016.06.004 |
0.462 |
|
| 2016 |
Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. International Journal of Hematology. PMID 27262700 DOI: 10.1007/S12185-016-2039-6 |
0.51 |
|
| 2016 |
Sadelain M. Tales of Antigen Evasion from CAR Therapy. Cancer Immunology Research. 4: 473. PMID 27252092 DOI: 10.1158/2326-6066.Cir-16-0089 |
0.34 |
|
| 2016 |
Hasan AN, Selvakumar A, Shabrova E, Liu XR, Afridi F, Heller G, Riviere I, Sadelain M, Dupont B, O'Reilly RJ. Soluble and membrane bound IL-15 Rα/IL-15 complexes mediate proliferation of high avidity central memory CD8(+) T-cells for adoptive immunotherapy of cancer and infections. Clinical and Experimental Immunology. PMID 27227483 DOI: 10.1111/Cei.12816 |
0.541 |
|
| 2016 |
Mansilla-Soto J, Riviere I, Boulad F, Sadelain M. Cell and gene therapy for the beta-thalassemias: advances and prospects. Human Gene Therapy. PMID 27021486 DOI: 10.1089/Hum.2016.037 |
0.412 |
|
| 2016 |
Themeli M, Sadelain M. Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response. Trends in Molecular Medicine. PMID 26971630 DOI: 10.1016/J.Molmed.2016.02.009 |
0.476 |
|
| 2016 |
Sadelain M. A New Induction to the Gene and Cell Therapy Hall Of Fame: Genome Editing. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 407-8. PMID 26952914 DOI: 10.1038/Mt.2016.25 |
0.437 |
|
| 2016 |
Kotini AG, de Stanchina E, Themeli M, Sadelain M, Papapetrou EP. Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene. Molecular Therapy. Nucleic Acids. 5: e284. PMID 26836371 DOI: 10.1038/Mtna.2015.57 |
0.672 |
|
| 2016 |
Geyer MB, Park JH, Riviere I, Wang X, Purdon T, Sadelain M, Brentjens RJ. Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. Journal of Clinical Oncology. 34: 7526-7526. DOI: 10.1200/Jco.2016.34.15_Suppl.7526 |
0.483 |
|
| 2016 |
Park JH, Riviere I, Wang X, Purdon T, Sadelain M, Brentjens RJ. Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. Journal of Clinical Oncology. 34: 7003-7003. DOI: 10.1200/Jco.2016.34.15_Suppl.7003 |
0.441 |
|
| 2016 |
Geyer MB, Park JH, Riviere I, Senechal B, Wang X, Purdon TJ, Sadelain MW, Brentjens RJ. Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL Blood. 128: 58-58. DOI: 10.1182/blood.V128.22.58.58 |
0.36 |
|
| 2016 |
Perna F, Berman S, Mansilla-Soto J, Hamieh M, Juthani R, Soni R, Eyquem J, Hendrickson R, Brennan C, Sadelain M. Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets Blood. 128: 526-526. DOI: 10.1182/Blood.V128.22.526.526 |
0.495 |
|
| 2016 |
Curran KJ, Silverman LB, Kobos R, Kernan NA, Margossian SP, Park JH, Sauter CS, Szenes V, Wang X, O'Reilly RJ, Sadelain M, Riviere I, Brentjens RJ. Abstract IA07: Chimeric antigen receptor T cells for cancer immunotherapy Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Ia07 |
0.635 |
|
| 2016 |
Stegen SJCvd, Themeli M, Eyquem J, Mansilla-Soto J, Sadelain M. Abstract 2309: T-cell development from T cell-derived induced pluripotent stem cell Cancer Research. 76: 2309-2309. DOI: 10.1158/1538-7445.Am2016-2309 |
0.543 |
|
| 2016 |
Wang X, Qu J, Stefanski J, Borquez-Ojeda O, Hack A, He Q, Wasielewska T, Du F, Sadelain M, Rivière I. 459. Evaluation of Miltenyi ExpAct and TransAct CD3/28 Beads for CAR-T Cell Manufacturing Molecular Therapy. 24: S182. DOI: 10.1016/S1525-0016(16)33268-3 |
0.502 |
|
| 2016 |
Eyquem J, Mansilla-Soto J, Odak A, Sadelain M. 274. One-Step Generation of Universal CAR T Cells Molecular Therapy. 24: S109. DOI: 10.1016/S1525-0016(16)33083-0 |
0.551 |
|
| 2016 |
DeSelm C, Hamieh M, Sadelain M. Radiation Sensitizes Tumor Cells to CAR T Cell Immunotherapy International Journal of Radiation Oncology*Biology*Physics. 96: S127. DOI: 10.1016/J.Ijrobp.2016.06.310 |
0.431 |
|
| 2016 |
Geyer M, Park J, Rivière I, Senechal B, Hsu M, Wang X, Purdon T, Sadelain M, Brentjens R. Phase I trial: CD19-Targeted CAR T-Cells in Patients with Residual CLL Following Initial Purine Analog-Based Therapy Clinical Lymphoma Myeloma and Leukemia. 16: S48. DOI: 10.1016/J.Clml.2016.07.069 |
0.432 |
|
| 2015 |
Sun J, Sadelain M. The quest for spatio-temporal control of CAR T cells. Cell Research. PMID 26575974 DOI: 10.1038/Cr.2015.131 |
0.456 |
|
| 2015 |
Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discovery. PMID 26503962 DOI: 10.1158/2159-8290.Cd-15-0583 |
0.499 |
|
| 2015 |
Zhao Z, Condomines M, van der Stegen SJ, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell. 28: 415-28. PMID 26461090 DOI: 10.1016/J.Ccell.2015.09.004 |
0.483 |
|
| 2015 |
Sadelain M. CAR therapy: the CD19 paradigm. The Journal of Clinical Investigation. 125: 3392-400. PMID 26325036 DOI: 10.1172/Jci80010 |
0.521 |
|
| 2015 |
Friedmann T, Jonlin EC, King NM, Torbett BE, Wivel NA, Kaneda Y, Sadelain M. ASGCT and JSGT Joint Position Statement on Human Genomic Editing. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 1282. PMID 26227250 DOI: 10.1038/Mt.2015.118 |
0.323 |
|
| 2015 |
van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nature Reviews. Drug Discovery. 14: 499-509. PMID 26129802 DOI: 10.1038/Nrd4597 |
0.504 |
|
| 2015 |
Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. Plos One. 10: e0130518. PMID 26110267 DOI: 10.1371/Journal.Pone.0130518 |
0.502 |
|
| 2015 |
Karponi G, Psatha N, Lederer CW, Adair JE, Zervou F, Zogas N, Kleanthous M, Tsatalas C, Anagnostopoulos A, Sadelain M, Rivière I, Stamatoyannopoulos G, Yannaki E. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood. PMID 26089395 DOI: 10.1182/Blood-2015-03-629618 |
0.409 |
|
| 2015 |
Sadelain M, Brentjens R, Rivière I, Park J. CD19 CAR Therapy for Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 35: e360-3. PMID 25993197 DOI: 10.14694/EdBook_AM.2015.35.e360 |
0.375 |
|
| 2015 |
Miller JF, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell. 27: 439-49. PMID 25858803 DOI: 10.1016/J.Ccell.2015.03.007 |
0.374 |
|
| 2015 |
Themeli M, Rivière I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 16: 357-66. PMID 25842976 DOI: 10.1016/J.Stem.2015.03.011 |
0.516 |
|
| 2015 |
Perna F, Vu LP, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine RL, Studer L, Sadelain M, Nimer SD. The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells. Stem Cell Reports. 4: 658-69. PMID 25754204 DOI: 10.1016/J.Stemcr.2015.02.003 |
0.64 |
|
| 2015 |
Wang X, Olszewska M, Qu J, Wasielewska T, Bartido S, Hermetet G, Sadelain M, Rivière I. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 127-35. PMID 25751502 DOI: 10.1097/Cji.0000000000000072 |
0.462 |
|
| 2015 |
Sauter CS, Riviere I, Bernal Y, Wang X, Purdon T, Yoo S, Moskowitz CH, Giralt S, Matasar MJ, Curran KJ, Park JH, Sadelain M, Brentjens RJ. Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). Journal of Clinical Oncology. 33: 8515-8515. DOI: 10.1200/Jco.2015.33.15_Suppl.8515 |
0.457 |
|
| 2015 |
Park JH, Riviere I, Wang X, Bernal Y, Purdon T, Halton E, Curran KJ, Sauter CS, Sadelain M, Brentjens RJ. Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. Journal of Clinical Oncology. 33: 7010-7010. DOI: 10.1200/Jco.2015.33.15_Suppl.7010 |
0.422 |
|
| 2015 |
Sadelain M. From T-cell Engineering to CAR therapy: Progress and Prospects Blood. 126: SCI-23-SCI-23. DOI: 10.1182/Blood.V126.23.Sci-23.Sci-23 |
0.522 |
|
| 2015 |
Park JH, Riviere I, Wang X, Bernal Y, Purdon T, Halton E, Wang Y, Curran KJ, Sauter CS, Sadelain M, Brentjens RJ. Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL Blood. 126: 682-682. DOI: 10.1182/Blood.V126.23.682.682 |
0.448 |
|
| 2015 |
Curran KJ, Riviere I, Silverman LB, Kobos R, Shukla N, Steinherz PG, Boulad F, Prockop S, Scaradavou A, Margossian SP, Wang X, Wang Y, Szenes V, Dansereau CH, MacKinnon B, ... ... Sadelain M, et al. Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL Blood. 126: 2533-2533. DOI: 10.1182/Blood.V126.23.2533.2533 |
0.631 |
|
| 2015 |
Park JH, Riviere I, Wang X, Bernal Y, Halton E, Quintanilla H, Curran K, Sauter C, Sadelain M, Brentjens RJ. 475. Phase I Clinical Trial of Autologous CD19-Targeted 19-28z CAR T Cells in Adult Patients With Relapsed or Refractory B-ALL Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34084-9 |
0.419 |
|
| 2015 |
Mansilla-Soto J, Leifman Y, Sadelain M. 343. Repair of the Sickle-Cell Disease Mutation in Human Stem Cells Using CRISPR/Cas9 and Single-Stranded Oligodeoxynucleotides Molecular Therapy. 23: S137. DOI: 10.1016/S1525-0016(16)33952-1 |
0.412 |
|
| 2015 |
Uchibori R, Teruya T, Ninomiya S, Ido H, Tsukahara T, Ohmine K, Urabe M, Saga Y, Kume A, Mizukami H, Riviere I, Sadelain M, Brentjens RJ, Mineno J, Ozawa K. 225. Activation Signals from CD19-CAR Permit NFAT-Controlled Inducible Expression of Transgenes in PBMCs Molecular Therapy. 23: S89. DOI: 10.1016/S1525-0016(16)33830-8 |
0.487 |
|
| 2015 |
Zhao Z, van der Stegen SJ, Condomines M, Perna F, Gunset G, Plotkin J, Sadelain M. 207. Optimal Activation of Both CD28 and 4-1BB in CAR-Targeted T Cells Results in Enhanced Tumor Eradication Molecular Therapy. 23: S82. DOI: 10.1016/S1525-0016(16)33812-6 |
0.513 |
|
| 2014 |
Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, ... ... Sadelain M, et al. T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1564-1574. PMID 28153204 DOI: 10.1038/mt.2014.148 |
0.512 |
|
| 2014 |
Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Science Translational Medicine. 6: 261ra151. PMID 25378643 DOI: 10.1126/Scitranslmed.3010162 |
0.522 |
|
| 2014 |
Oricchio E, Papapetrou EP, Lafaille F, Ganat YM, Kriks S, Ortega-Molina A, Mark WH, Teruya-Feldstein J, Huse JT, Reuter V, Sadelain M, Studer L, Wendel HG. A cell engineering strategy to enhance the safety of stem cell therapies. Cell Reports. 8: 1677-85. PMID 25242333 DOI: 10.1016/J.Celrep.2014.08.039 |
0.644 |
|
| 2014 |
Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, ... ... Sadelain M, et al. T-cell immunotherapy: looking forward. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1564-74. PMID 25186558 DOI: 10.1038/Mt.2014.148 |
0.579 |
|
| 2014 |
Fedorov VD, Sadelain M, Kloss CC. Novel approaches to enhance the specificity and safety of engineered T cells. Cancer Journal (Sudbury, Mass.). 20: 160-5. PMID 24667964 DOI: 10.1097/Ppo.0000000000000040 |
0.475 |
|
| 2014 |
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, ... ... Sadelain M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine. 6: 224ra25. PMID 24553386 DOI: 10.1126/Scitranslmed.3008226 |
0.504 |
|
| 2014 |
Boulad F, Wang X, Qu J, Taylor C, Ferro L, Karponi G, Bartido S, Giardina P, Heller G, Prockop SE, Maggio A, Sadelain M, Rivière I. Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 123: 1483-6. PMID 24429337 DOI: 10.1182/Blood-2013-06-507178 |
0.402 |
|
| 2014 |
Janovitz T, Oliveira T, Sadelain M, Falck-Pedersen E. Highly divergent integration profile of adeno-associated virus serotype 5 revealed by high-throughput sequencing. Journal of Virology. 88: 2481-8. PMID 24335317 DOI: 10.1128/Jvi.03419-13 |
0.304 |
|
| 2014 |
Park JH, Riviere I, Wang X, Bartido S, Sadelain M, Brentjens RJ. Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL. Journal of Clinical Oncology. 32: 7020-7020. DOI: 10.1200/Jco.2014.32.15_Suppl.7020 |
0.467 |
|
| 2014 |
Sadelain M, Condomines M, Zhao Z, Brentjens RJ, Riviere I. Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer immunotherapy. Journal of Clinical Oncology. 32: 3022-3022. DOI: 10.1200/Jco.2014.32.15_Suppl.3022 |
0.427 |
|
| 2014 |
Sauter CS, Riviere I, Bernal YJ, Wang X, Purdon TJ, Yoo S, Moskowitz CH, Giralt S, Matasar MJ, Curran KJ, Park JH, Sadelain M, Brentjens RJ. Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL) Blood. 124: 677-677. DOI: 10.1182/Blood.V124.21.677.677 |
0.461 |
|
| 2014 |
Park JH, Riviere I, Wang X, Bernal YJ, Yoo S, Purdon T, Halton E, Quintanilla H, Curran KJ, Sauter CS, Davila ML, Sadelain M, Brentjens RJ. CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL Blood. 124: 382-382. DOI: 10.1182/Blood.V124.21.382.382 |
0.466 |
|
| 2014 |
Curran KJ, Riviere I, Kobos R, Kernan NA, Boulad F, Prockop SE, Scaradavou A, Renaud TM, Shukla N, Steinherz PG, Park JH, Sauter CS, O'Reilly RJ, Sadelain M, Brentjens RJ. Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL Blood. 124: 3716-3716. DOI: 10.1182/Blood.V124.21.3716.3716 |
0.631 |
|
| 2014 |
Sadelain M, Brentjens R, Davila M, Riviere I, Wang X, Bartido S, Park J, Bouhassira D, Curran K, Chung S, Stefanski J, Borquez-Ojeda O, Giralt S. Abstract CT102: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct102 |
0.513 |
|
| 2014 |
Cherkassky L, Villena-Vargas J, Morello A, Rusch VW, Sadelain M, Adusumilli P. Mesothelin-targeted T Cells Gene-Engineered with 4-1BB Costimulation Overcome Tumor-Mediated Immunoinhibition and Eradicate Established Solid Tumors Journal of the American College of Surgeons. 219: S134. DOI: 10.1016/J.Jamcollsurg.2014.07.320 |
0.393 |
|
| 2014 |
Sadelain M. CAR T cell therapy and the promise of T cell engineering Experimental Hematology. 42: S3. DOI: 10.1016/J.Exphem.2014.07.010 |
0.461 |
|
| 2013 |
Wang X, Hullings M, Arauz G, Bartido S, Lewis JS, Schöder H, Zanzonico P, Scher HI, Sadelain M, Riviere I. Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 72. PMID 28137105 DOI: 10.1200/jco.2013.31.6_suppl.72 |
0.401 |
|
| 2013 |
Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine. 5: 215ra172. PMID 24337479 DOI: 10.1126/Scitranslmed.3006597 |
0.479 |
|
| 2013 |
Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (New York, N.Y.). 15: 1172-83. PMID 24204196 DOI: 10.1593/Neo.13986 |
0.34 |
|
| 2013 |
Stancevic B, Varda-Bloom N, Cheng J, Fuller JD, Rotolo JA, García-Barros M, Feldman R, Rao S, Weichselbaum RR, Harats D, Haimovitz-Friedman A, Fuks Z, Sadelain M, Kolesnick R. Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure. Plos One. 8: e69025. PMID 23936314 DOI: 10.1371/Journal.Pone.0069025 |
0.337 |
|
| 2013 |
Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nature Biotechnology. 31: 928-33. PMID 23934177 DOI: 10.1038/Nbt.2678 |
0.546 |
|
| 2013 |
Tsukahara T, Ohmine K, Yamamoto C, Uchibori R, Ido H, Teruya T, Urabe M, Mizukami H, Kume A, Nakamura M, Mineno J, Takesako K, Riviere I, Sadelain M, Brentjens R, et al. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. Biochemical and Biophysical Research Communications. 438: 84-9. PMID 23872144 DOI: 10.1016/J.Bbrc.2013.07.030 |
0.476 |
|
| 2013 |
Ghosh A, Holland AM, Dogan Y, Yim NL, Rao UK, Young LF, West ML, Singer NV, Lee H, Na IK, Tsai JJ, Jenq RR, Penack O, Hanash AM, Lezcano C, ... ... Sadelain M, et al. PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Research. 73: 4687-96. PMID 23733752 DOI: 10.1158/0008-5472.Can-12-4699 |
0.485 |
|
| 2013 |
Janovitz T, Klein IA, Oliveira T, Mukherjee P, Nussenzweig MC, Sadelain M, Falck-Pedersen E. High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. Journal of Virology. 87: 8559-68. PMID 23720718 DOI: 10.1128/Jvi.01135-13 |
0.314 |
|
| 2013 |
Ghosh A, Dogan Y, Moroz M, Holland AM, Yim NL, Rao UK, Young LF, Tannenbaum D, Masih D, Velardi E, Tsai JJ, Jenq RR, Penack O, Hanash AM, Smith OM, ... ... Sadelain M, et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. The Journal of Clinical Investigation. 123: 2654-62. PMID 23676461 DOI: 10.1172/Jci66301 |
0.499 |
|
| 2013 |
Davila ML, Kloss CC, Gunset G, Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. Plos One. 8: e61338. PMID 23585892 DOI: 10.1371/Journal.Pone.0061338 |
0.475 |
|
| 2013 |
Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discovery. 3: 388-98. PMID 23550147 DOI: 10.1158/2159-8290.Cd-12-0548 |
0.477 |
|
| 2013 |
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, ... ... Sadelain M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Translational Medicine. 5: 177ra38. PMID 23515080 DOI: 10.1126/Scitranslmed.3005930 |
0.534 |
|
| 2013 |
Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 490-8. PMID 23269987 DOI: 10.1200/Jco.2012.45.2052 |
0.323 |
|
| 2013 |
Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology. 31: 71-5. PMID 23242161 DOI: 10.1038/Nbt.2459 |
0.469 |
|
| 2013 |
Rafii S, Kloss CC, Butler JM, Ginsberg M, Gars E, Lis R, Zhan Q, Josipovic P, Ding BS, Xiang J, Elemento O, Zaninovic N, Rosenwaks Z, Sadelain M, Rafii JA, et al. Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. Blood. 121: 770-80. PMID 23169780 DOI: 10.1182/Blood-2012-07-444208 |
0.397 |
|
| 2013 |
Kohn DB, Pai SY, Sadelain M. Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: S64-9. PMID 23032601 DOI: 10.1016/J.Bbmt.2012.09.021 |
0.378 |
|
| 2013 |
Park JH, Rivière I, Wang X, Stefanski J, He Q, Borquez-Ojeda O, Wasielewska T, Taylor C, Qu J, Bartido S, Bernal YJ, Sadelain M, Brentjens RJ. Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL Blood. 122: 874-874. DOI: 10.1182/blood.V122.21.874.874 |
0.411 |
|
| 2013 |
Boulad F, Riviere I, Wang X, Bartido S, Prockop SE, Barone R, Moi P, Maggio A, Sadelain M. First US Phase I Clinical Trial Of Globin Gene Transfer For The Treatment Of Beta-Thalassemia Major Blood. 122: 716-716. DOI: 10.1182/Blood.V122.21.716.716 |
0.444 |
|
| 2013 |
Davila ML, Riviere I, Wang X, Bartido S, Stefanski J, He Q, Borquez-Ojeda O, Taylor C, Wasielewska T, Qu J, Bouhassira DC, Bernal YJ, Yoo S, Purdon T, Halton E, ... ... Sadelain M, et al. Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Blood. 122: 69-69. DOI: 10.1182/Blood.V122.21.69.69 |
0.479 |
|
| 2013 |
Fedorov V, Themeli M, Sadelain M. Inhibitory chimeric antigen receptors (iCARs) limit undesirable side effects of T-cell therapies Experimental Hematology. 41: S75. DOI: 10.1016/J.Exphem.2013.05.298 |
0.44 |
|
| 2012 |
Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology. 1: 1577-1583. PMID 23264903 DOI: 10.4161/Onci.22524 |
0.512 |
|
| 2012 |
June C, Rosenberg SA, Sadelain M, Weber JS. T-cell therapy at the threshold. Nature Biotechnology. 30: 611-4. PMID 22781680 DOI: 10.1038/Nbt.2305 |
0.47 |
|
| 2012 |
Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2478-89. PMID 22371455 DOI: 10.1158/1078-0432.Ccr-11-2614 |
0.368 |
|
| 2012 |
Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 119: 4133-41. PMID 22354001 DOI: 10.1182/Blood-2011-12-400044 |
0.479 |
|
| 2012 |
Migliaccio AR, Whitsett C, Papayannopoulou T, Sadelain M. The potential of stem cells as an in vitro source of red blood cells for transfusion. Cell Stem Cell. 10: 115-9. PMID 22305561 DOI: 10.1016/J.Stem.2012.01.001 |
0.379 |
|
| 2012 |
Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nature Reviews. Cancer. 12: 51-8. PMID 22129804 DOI: 10.1038/Nrc3179 |
0.585 |
|
| 2012 |
Rivière I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood. 119: 1107-16. PMID 22096239 DOI: 10.1182/Blood-2011-09-349993 |
0.406 |
|
| 2012 |
Slovin SF, Wang X, Borquez-Ojeda O, Stefanski J, Olszewska M, Taylor C, Bartido S, Scher HI, Sadelain M, Riviere I. Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells. Journal of Clinical Oncology. 30: TPS4700-TPS4700. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps4700 |
0.518 |
|
| 2012 |
Davila ML, Riviere I, Wang X, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, Frattini MG, Sadelain M, Brentjens RJ. A phase I clinical trial of autologous, anti-CD19 gene targeted T cells for adults with B cell acute lymphoblastic leukemia (B-ALL). Journal of Clinical Oncology. 30: TPS2619-TPS2619. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2619 |
0.527 |
|
| 2012 |
Ghosh A, Davila ML, Young LF, Kloss C, Gunset G, Smith OM, West ML, Singer NV, Holland AM, Jenq RR, Hanash AM, Dudakov JA, Velardi E, Shono Y, Sadelain M, et al. CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated Gvhd Blood. 120: 451-451. DOI: 10.1182/Blood.V120.21.451.451 |
0.5 |
|
| 2012 |
Davila ML, Riviere I, Wang X, Park JH, Stefanski J, Taylor C, He Q, Olszewska M, Wasielewska T, Borquez-Ojeda O, Qu J, Bartido S, Jurcic JG, Douer D, Frattini MG, ... Sadelain M, et al. Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells Blood. 120: 3566-3566. DOI: 10.1182/Blood.V120.21.3566.3566 |
0.53 |
|
| 2012 |
Curran KJ, Kernan NA, Wang X, Taylor C, Doubrovina E, Bartido S, Sadelain M, O'Reilly RJ, Brentjens RJ, Rivière I. CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT Blood. 120: 353-353. DOI: 10.1182/Blood.V120.21.353.353 |
0.617 |
|
| 2012 |
Davila ML, Kloss C, Brentjens RJ, Sadelain M. Conditioning Intensity and T Cell Dose Determine Efficacy of CD19-Targeted T Cell-Mediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL. Blood. 120: 2613-2613. DOI: 10.1182/Blood.V120.21.2613.2613 |
0.533 |
|
| 2012 |
Perna F, Vu LP, Themeli M, Hoya-Arias R, Liu F, Wang L, Gurvich N, Hricik T, Papapetrou EP, Moore MAA, Levine RL, Sadelain M, Nimer S. L3MBTL1: A Polycomb Protein At the Node of Crosstalk Between the BMP4 and Hippo Signaling Pathways in Erythropoiesis. Blood. 120: 2296-2296. DOI: 10.1182/Blood.V120.21.2296.2296 |
0.652 |
|
| 2012 |
Hasan AN, Ricafort RJ, Selvakumar A, Doubrovina E, Riviere I, Sadelain M, O'Reilly RJ. Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific Th1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes Blood. 120: 1905-1905. DOI: 10.1182/Blood.V120.21.1905.1905 |
0.531 |
|
| 2012 |
Park JH, Rivière I, Wang X, Stefanski J, He Q, Taylor C, Olszewska M, Wasielewska T, Bartido S, Davila ML, Bernal Y, Lamanna N, Noy A, Sadelain M, Brentjens RJ. Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL Blood. 120: 1797-1797. DOI: 10.1182/Blood.V120.21.1797.1797 |
0.509 |
|
| 2012 |
Benjamin R, Condomines M, Gunset G, Sadelain M. Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma Cancer Research. 72: 3499-3499. DOI: 10.1158/1538-7445.Am2012-3499 |
0.482 |
|
| 2012 |
Poon S, Kloss C, Sadelain M. 317 BLOCKADE OF TGFβ ENHANCES EFFICACY OF GENETICALLY MODIFIED HUMAN T CELLS TARGETED AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.377 |
0.39 |
|
| 2011 |
Brentjens RJ, Riviere I, Park J, Davilla M, Wang X, Yeh R, Lamanna N, Frattini MG, Sadelain M. Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2534. PMID 28022329 DOI: 10.1200/Jco.2011.29.15_Suppl.2534 |
0.496 |
|
| 2011 |
Sadelain M. Eliminating cells gone astray. The New England Journal of Medicine. 365: 1735-7. PMID 22047566 DOI: 10.1056/Nejme1109971 |
0.451 |
|
| 2011 |
Ghinassi B, Ferro L, Masiello F, Tirelli V, Sanchez M, Migliaccio G, Whitsett C, Kachala S, Riviere I, Sadelain M, Migliaccio AR. Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγ mice. Stem Cells International. 2011: 673752. PMID 21912558 DOI: 10.4061/2011/673752 |
0.337 |
|
| 2011 |
Papapetrou EP, Sadelain M. Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites. Nature Protocols. 6: 1274-89. PMID 21886096 DOI: 10.1038/Nprot.2011.362 |
0.632 |
|
| 2011 |
Papapetrou EP, Sadelain M. Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nature Protocols. 6: 1251-73. PMID 21886095 DOI: 10.1038/Nprot.2011.374 |
0.634 |
|
| 2011 |
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, ... ... Sadelain M, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118: 4817-28. PMID 21849486 DOI: 10.1182/Blood-2011-04-348540 |
0.53 |
|
| 2011 |
Condomines M, Sadelain M. Tolerance induction by allogeneic hematopoietic stem cells. Cell Stem Cell. 9: 87-8. PMID 21816356 DOI: 10.1016/J.Stem.2011.07.005 |
0.399 |
|
| 2011 |
Mansilla-Soto J, Rivière I, Sadelain M. Genetic strategies for the treatment of sickle cell anaemia. British Journal of Haematology. 154: 715-27. PMID 21707580 DOI: 10.1111/J.1365-2141.2011.08773.X |
0.426 |
|
| 2011 |
Kim H, Lee G, Ganat Y, Papapetrou EP, Lipchina I, Socci ND, Sadelain M, Studer L. miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell. 8: 695-706. PMID 21624813 DOI: 10.1016/J.Stem.2011.04.002 |
0.609 |
|
| 2011 |
Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Research. 71: 2871-81. PMID 21487038 DOI: 10.1158/0008-5472.Can-10-0552 |
0.516 |
|
| 2011 |
Brady T, Roth SL, Malani N, Wang GP, Berry CC, Leboulch P, Hacein-Bey-Abina S, Cavazzana-Calvo M, Papapetrou EP, Sadelain M, Savilahti H, Bushman FD. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Research. 39: e72. PMID 21415009 DOI: 10.1093/Nar/Gkr140 |
0.615 |
|
| 2011 |
Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 432-8. PMID 21358705 DOI: 10.1038/Mt.2011.1 |
0.426 |
|
| 2011 |
Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nature Biotechnology. 29: 73-8. PMID 21151124 DOI: 10.1038/Nbt.1717 |
0.69 |
|
| 2011 |
Papapetrou EP, Sadelain M, Bushman F. Genomic Safe Harbors in Human iPS Cells Blood. 118: SCI-47-SCI-47. DOI: 10.1182/Blood.V118.21.Sci-47.Sci-47 |
0.673 |
|
| 2011 |
Ghosh A, Dogan Y, Holland AM, Smith OM, Young LF, West ML, Singer NV, Jenq RR, Na I, Penack O, Hanash AM, Sauer MG, Sadelain M, van den Brink MR. Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC Blood. 118: 817-817. DOI: 10.1182/Blood.V118.21.817.817 |
0.527 |
|
| 2011 |
Maus MV, Riviere I, Borquez-Ojeda O, Wang X, Yuan J, Merghoub T, Plotkin J, O’Reilly RJ, Wolchok JD, Sadelain M. Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma Blood. 118: 4309-4309. DOI: 10.1182/Blood.V118.21.4309.4309 |
0.53 |
|
| 2011 |
Perna F, Vu LP, Themeli M, Hoya-Arias R, Zhao X, Papapetrou EP, Sadelain M, Nimer SD. Targeting a Novel Epigenetic Silencing Mechanism to Efficiently Upregulate Fetal Globin Gene Expression Blood. 118: 352-352. DOI: 10.1182/Blood.V118.21.352.352 |
0.666 |
|
| 2011 |
Park JH, Yeh R, Riviere I, Sadelain M, Brentjens R. In Vivo comparison of 3 Suicide Gene-Prodrug Combinations in a Mouse Graft-Versus-Host-Disease Model Blood. 118: 3121-3121. DOI: 10.1182/Blood.V118.21.3121.3121 |
0.456 |
|
| 2011 |
Ghinassi B, Themeli M, Chang K, Halverson G, Hashmi G, Sadelain M, Papayannopoulou T, Migliaccio ARF, Whitsett C. Comparative Blood Group Profiling of Human Erythroid Cells (EBs) Generated from Adult Blood (AB), Cord Blood (CB), Human Embryonic Stem Cells (hESC) and Induced Pluripotent Stem Cells (iPS) Blood. 118: 1027-1027. DOI: 10.1182/Blood.V118.21.1027.1027 |
0.388 |
|
| 2011 |
Ghosh A, Holland AM, Dogan Y, Yim N, Rao UK, Young LF, Smith OM, Jenq R, Na I, Tsai JJ, Singer N, West M, Penack O, Hanash AM, Sant'Angelo D, ... Sadelain M, et al. Abstract 4743: Genetically engineered allogeneic T Cells for BMT immunotherapy: Expression of TRAIL and PLZF selectively enhances GVT and abrogates GVHD Cancer Research. 71: 4743-4743. DOI: 10.1158/1538-7445.Am2011-4743 |
0.522 |
|
| 2011 |
Park D, Park J, Zhong X, Sadelain M. Estimation of empirical null using a mixture of normals and its use in local false discovery rate Computational Statistics and Data Analysis. 55: 2421-2432. DOI: 10.1016/J.Csda.2011.02.009 |
0.311 |
|
| 2010 |
Sadelain M. The need for genetically engineering therapeutic pluripotent stem cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 2039. PMID 21119687 DOI: 10.1038/Mt.2010.244 |
0.442 |
|
| 2010 |
Sadelain M. RORing T cells target CLL and MCL. Blood. 116: 4387-8. PMID 21109622 DOI: 10.1182/Blood-2010-09-303388 |
0.478 |
|
| 2010 |
Papapetrou EP, Sadelain M. Reconstructing blood from induced pluripotent stem cells. F1000 Medicine Reports. 2. PMID 20948840 DOI: 10.3410/M2-44 |
0.65 |
|
| 2010 |
Ellis J, Baum C, Benvenisty N, Mostoslavsky G, Okano H, Stanford WL, Porteus M, Sadelain M. Benefits of utilizing gene-modified iPSCs for clinical applications. Cell Stem Cell. 7: 429-30. PMID 20887948 DOI: 10.1016/J.Stem.2010.09.010 |
0.46 |
|
| 2010 |
Likar Y, Zurita J, Dobrenkov K, Shenker L, Cai S, Neschadim A, Medin JA, Sadelain M, Hricak H, Ponomarev V. A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1395-403. PMID 20810757 DOI: 10.2967/Jnumed.109.074344 |
0.322 |
|
| 2010 |
Sadelain M, Rivière I, Wang X, Boulad F, Prockop S, Giardina P, Maggio A, Galanello R, Locatelli F, Yannaki E. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Annals of the New York Academy of Sciences. 1202: 52-8. PMID 20712772 DOI: 10.1111/J.1749-6632.2010.05597.X |
0.43 |
|
| 2010 |
Yang JS, Maurin T, Robine N, Rasmussen KD, Jeffrey KL, Chandwani R, Papapetrou EP, Sadelain M, O'Carroll D, Lai EC. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 15163-8. PMID 20699384 DOI: 10.1073/Pnas.1006432107 |
0.537 |
|
| 2010 |
Na IK, Markley JC, Tsai JJ, Yim NL, Beattie BJ, Klose AD, Holland AM, Ghosh A, Rao UK, Stephan MT, Serganova I, Santos EB, Brentjens RJ, Blasberg RG, Sadelain M, et al. Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood. 116: e18-25. PMID 20511541 DOI: 10.1182/Blood-2009-12-259432 |
0.489 |
|
| 2010 |
Schroten C, Kraaij R, Veldhoven JL, Berrevoets CA, den Bakker MA, Ma Q, Sadelain M, Bangma CH, Willemsen RA, Debets R. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. Journal of Immunological Methods. 359: 11-20. PMID 20460126 DOI: 10.1016/J.Jim.2010.04.006 |
0.481 |
|
| 2010 |
Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 666-8. PMID 20357779 DOI: 10.1038/Mt.2010.31 |
0.381 |
|
| 2010 |
Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 115: 3508-19. PMID 20190192 DOI: 10.1182/Blood-2009-09-241398 |
0.386 |
|
| 2010 |
Papapetrou EP, Korkola JE, Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells (Dayton, Ohio). 28: 287-96. PMID 19911427 DOI: 10.1002/Stem.257 |
0.549 |
|
| 2010 |
Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 413-20. PMID 19773745 DOI: 10.1038/Mt.2009.210 |
0.451 |
|
| 2010 |
Park JH, Yeh R, Riviere I, Sadelain M, Brentjens RJ. In vitro analysis of suicide gene expression and function in human T lymphocytes transduced to express a tumor-targeted chimeric antigen receptor. Journal of Clinical Oncology. 28: e13124-e13124. DOI: 10.1200/Jco.2010.28.15_Suppl.E13124 |
0.452 |
|
| 2010 |
Ghosh A, Holland AM, Dogan Y, Yim N, Rao UK, Young LF, Smith OM, Jenq R, Na I, Tsai J, Penack O, Hanash AM, Sauer MG, Sant'Angelo D, Sadelain M, et al. Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd Blood. 116: 730-730. DOI: 10.1182/Blood.V116.21.730.730 |
0.532 |
|
| 2010 |
Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman F, Studer L, Sadelain M. Therapeutic Transgene Expression From Genomic Safe Harbors In Patient-Specific Induced Pluripotent Stem Cells Blood. 116: 564-564. DOI: 10.1182/Blood.V116.21.564.564 |
0.649 |
|
| 2010 |
Park JH, Yeh R, Rivière I, Sadelain M, Brentjens RJ. In Vitro analysis of Suicide Gene Expression and Function of 3 Suicide Gene-Prodrug Combinations In Human T Lymphocytes Further Modified to Express the CD19 Targeted 19–28z Chimeric Antigen Receptor. Blood. 116: 3771-3771. DOI: 10.1182/Blood.V116.21.3771.3771 |
0.493 |
|
| 2010 |
Ghinassi B, Ferro L, Kachala S, Riviere I, Sadelain M, Migliaccio ARF. Recovery and Biodistribution of Ex-Vivo Expanded Human Erythroblasts Injected Into NOD/SCID/IL2Rγnull Mice Blood. 116: 338-338. DOI: 10.1182/Blood.V116.21.338.338 |
0.386 |
|
| 2010 |
Davila ML, Taylor C, Wang X, Stefanski J, Olszewska M, Bartido S, Frattini M, Sadelain M, Rivière I, Brentjens RJ. B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen Blood. 116: 3268-3268. DOI: 10.1182/Blood.V116.21.3268.3268 |
0.532 |
|
| 2010 |
Curran KJ, Taylor C, Doubrovina E, Wang X, O'Reilly RJ, Sadelain M, Kernan NA, Brentjens RJ, Riviere I. Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice Blood. 116: 2092-2092. DOI: 10.1182/Blood.V116.21.2092.2092 |
0.642 |
|
| 2010 |
Davila ML, Sadelain M. T Cells Genetically Targeted to CD19 Eradicate B-ALL In a Novel Syngeneic Mouse Disease Model Blood. 116: 171-171. DOI: 10.1182/Blood.V116.21.171.171 |
0.513 |
|
| 2010 |
Servais EL, Colovos C, Suzuki K, Rodriguez L, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Abstract 3229: Biomarker validation for a rare malignancy in a mouse model Cancer Research. 70: 3229-3229. DOI: 10.1158/1538-7445.Am10-3229 |
0.367 |
|
| 2010 |
Park J, Yeh R, Riviere I, Sadelain M, Brentjens R. Abstract 1944:In vitroanalysis of suicide gene expression and function in human T lymphocytes transduced to express a tumor targeted chimeric antigen receptor Cancer Research. 70: 1944-1944. DOI: 10.1158/1538-7445.Am10-1944 |
0.485 |
|
| 2009 |
Hasan AN, Selvakumar A, Doubrovina E, Riviere I, Sadelain MW, O'Reilly RJ. Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies. Discovery Medicine. 8: 210-8. PMID 20040272 |
0.575 |
|
| 2009 |
Sadelain M. T-cell engineering for cancer immunotherapy. Cancer Journal (Sudbury, Mass.). 15: 451-5. PMID 20010162 DOI: 10.1097/Ppo.0B013E3181C51F37 |
0.494 |
|
| 2009 |
Boulad F, Rivière I, Sadelain M. Gene therapy for homozygous beta-thalassemia. Is it a reality? Hemoglobin. 33: S188-96. PMID 20001625 DOI: 10.3109/03630260903351866 |
0.397 |
|
| 2009 |
Sadelain M, Chang A, Lisowski L. Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1994-9. PMID 19844194 DOI: 10.1038/Mt.2009.238 |
0.419 |
|
| 2009 |
Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of Immunology (Baltimore, Md. : 1950). 183: 5563-74. PMID 19843940 DOI: 10.4049/Jimmunol.0900447 |
0.416 |
|
| 2009 |
Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 461: 402-6. PMID 19693009 DOI: 10.1038/Nature08320 |
0.615 |
|
| 2009 |
Hasan AN, Kollen WJ, Trivedi D, Selvakumar A, Dupont B, Sadelain M, O'Reilly RJ. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. Journal of Immunology (Baltimore, Md. : 1950). 183: 2837-50. PMID 19635907 DOI: 10.4049/Jimmunol.0804178 |
0.618 |
|
| 2009 |
Papapetrou EP, Tomishima MJ, Chambers SM, Mica Y, Reed E, Menon J, Tabar V, Mo Q, Studer L, Sadelain M. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proceedings of the National Academy of Sciences of the United States of America. 106: 12759-64. PMID 19549847 DOI: 10.1073/Pnas.0904825106 |
0.637 |
|
| 2009 |
Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. The Prostate. 69: 1128-41. PMID 19367568 DOI: 10.1002/Pros.20962 |
0.369 |
|
| 2009 |
Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Current Opinion in Immunology. 21: 215-23. PMID 19327974 DOI: 10.1016/J.Coi.2009.02.009 |
0.486 |
|
| 2009 |
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnology. 27: 275-80. PMID 19252484 DOI: 10.1038/Nbt.1529 |
0.628 |
|
| 2009 |
Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 169-80. PMID 19238016 DOI: 10.1097/Cji.0B013E318194A6E8 |
0.525 |
|
| 2009 |
Hayakawa J, Ueda T, Lisowski L, Hsieh MM, Washington K, Phang O, Metzger M, Krouse A, Donahue RE, Sadelain M, Tisdale JF. Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate. Human Gene Therapy. 20: 563-72. PMID 19222366 DOI: 10.1089/Hum.2008.186 |
0.426 |
|
| 2009 |
Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M, Brentjens RJ. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nature Medicine. 15: 338-44. PMID 19219023 DOI: 10.1038/Nm.1930 |
0.498 |
|
| 2009 |
Lee J, Sadelain M, Brentjens R. Retroviral transduction of murine primary T lymphocytes. Methods in Molecular Biology (Clifton, N.J.). 506: 83-96. PMID 19110621 DOI: 10.1007/978-1-59745-409-4_7 |
0.493 |
|
| 2009 |
Papapetrou EP, Kovalovsky D, Beloeil L, Sant'angelo D, Sadelain M. Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. The Journal of Clinical Investigation. 119: 157-68. PMID 19033646 DOI: 10.1172/Jci37216 |
0.641 |
|
| 2009 |
Na I, Markley J, Tsai J, Yim NL, Beattie BJ, Klose AD, Holland AM, Ghosh A, Rao UK, Stephan M, Serganova I, Brentjens RJ, Blasberg RR, Sadelain MW, van den Brink MR. Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo. Blood. 114: 914-914. DOI: 10.1182/Blood.V114.22.914.914 |
0.413 |
|
| 2009 |
Brentjens RJ, Hollyman D, Park J, Santos E, Yeh R, Stefanski J, Taylor C, Weiss MA, Filippa D, Riviere I, Sadelain MW. Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells. Blood. 114: 3436-3436. DOI: 10.1182/blood.v114.22.3436.3436 |
0.423 |
|
| 2009 |
Servais EL, Velez MC, Rusch VW, Sadelain M, Adusumilli PS. Abstract B27: A preclinical mouse model of orthotopic pleural cancer that facilitates noninvasive quantitative monitoring of tumor progression and therapy response Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-B27 |
0.354 |
|
| 2009 |
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Erratum: Corrigendum: Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling Nature Biotechnology. 27: 485-485. DOI: 10.1038/Nbt0509-485A |
0.59 |
|
| 2008 |
Sadelain M, Boulad F, Lisowki L, Moi P, Riviere I. Stem cell engineering for the treatment of severe hemoglobinopathies. Current Molecular Medicine. 8: 690-7. PMID 18991654 DOI: 10.2174/156652408786241357 |
0.439 |
|
| 2008 |
Chang AH, Stephan MT, Lisowski L, Sadelain M. Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1745-52. PMID 18682698 DOI: 10.1038/Mt.2008.161 |
0.454 |
|
| 2008 |
Wang X, Olszewska M, Capacio V, Stefanski J, Przybylowski M, Samakoglu S, Chang AH, Sadelain M, Rivière I. Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gamma-retrovirus-encoded hsvtk suicide genes. Gene Therapy. 15: 1454-9. PMID 18563185 DOI: 10.1038/Gt.2008.103 |
0.397 |
|
| 2008 |
Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, Pillarsetty N, Hricak H, Sadelain M, Ponomarev V. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1162-70. PMID 18552144 DOI: 10.2967/Jnumed.107.047324 |
0.46 |
|
| 2008 |
Sadelain M, Williams DA. A "vector drain" in US gene therapy development? Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 801-2. PMID 18432266 DOI: 10.1038/Mt.2008.71 |
0.415 |
|
| 2008 |
Lisowski L, Sadelain M. Current status of globin gene therapy for the treatment of beta-thalassaemia. British Journal of Haematology. 141: 335-45. PMID 18410569 DOI: 10.1111/J.1365-2141.2008.07098.X |
0.404 |
|
| 2008 |
Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, ... Sadelain M, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature Biotechnology. 26: 453-61. PMID 18376399 DOI: 10.1038/Nbt1395 |
0.504 |
|
| 2008 |
Moi P, Sadelain M. Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells. Haematologica. 93: 325-30. PMID 18310536 DOI: 10.3324/Haematol.12732 |
0.374 |
|
| 2008 |
Brentjens RJ, Hollyman D, Weiss M, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Heaney M, Riviere I, Sadelain M. A phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19 Journal of Clinical Oncology. 26: 3045-3045. DOI: 10.1200/Jco.2008.26.15_Suppl.3045 |
0.498 |
|
| 2008 |
Lee J, Sadelain M, Brentjens RJ. Tumor-Targeted Human CD4+ CD25hi Regulatory T Cells Effectively Inhibit T Cell –mediated Rejection of CD19+ Tumors in An in Vivo xenotransplant Tumor Model Blood. 112: 3901-3901. DOI: 10.1182/Blood.V112.11.3901.3901 |
0.507 |
|
| 2008 |
Sadelain M. Transcriptional and post transcriptional gene regulation in stem cell-based gene therapy Blood Cells, Molecules, and Diseases. 40: 283. DOI: 10.1016/J.Bcmd.2007.10.074 |
0.357 |
|
| 2008 |
Papapetrou E, Kovalovsky D, Beloeil L, Sant'angelo D, Sadelain M. MicroRNA regulation directs lineage- and developmental stage-specific transgene expression in hematopoietic stem cell progeny Blood Cells, Molecules, and Diseases. 40: 280. DOI: 10.1016/J.Bcmd.2007.10.068 |
0.626 |
|
| 2007 |
Doubrovin MM, Doubrovina ES, Zanzonico P, Sadelain M, Larson SM, O'Reilly RJ. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer Research. 67: 11959-69. PMID 18089827 DOI: 10.1158/0008-5472.Can-07-1250 |
0.634 |
|
| 2007 |
Quintás-Cardama A, Yeh RK, Hollyman D, Stefanski J, Taylor C, Nikhamin Y, Imperato G, Sadelain M, Rivière I, Brentjens RJ. Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Human Gene Therapy. 18: 1253-60. PMID 18052719 DOI: 10.1089/Hum.2007.088 |
0.48 |
|
| 2007 |
Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine. 13: 1440-9. PMID 18026115 DOI: 10.1038/Nm1676 |
0.489 |
|
| 2007 |
Lisowski L, Sadelain M. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood. 110: 4175-8. PMID 17921347 DOI: 10.1182/Blood-2007-08-108647 |
0.417 |
|
| 2007 |
Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5426-35. PMID 17855649 DOI: 10.1158/1078-0432.Ccr-07-0674 |
0.507 |
|
| 2007 |
Yuan J, Kendle R, Ireland J, Heller G, Sadelain M, Young JW, Rivière I. Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 634-43. PMID 17667527 DOI: 10.1097/Cji.0B013E31804Efc8B |
0.479 |
|
| 2007 |
Han XD, Lin C, Chang J, Sadelain M, Kan YW. Fetal gene therapy of alpha-thalassemia in a mouse model. Proceedings of the National Academy of Sciences of the United States of America. 104: 9007-11. PMID 17496141 DOI: 10.1073/Pnas.0702457104 |
0.334 |
|
| 2007 |
Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 445-56. PMID 17228317 DOI: 10.1038/Sj.Mt.6300060 |
0.462 |
|
| 2007 |
Ricafort RJ, Stephan M, O’Reilly R, Sadelain M. In vitro expansion of CMV-specific CD4+ T-cells by artificial antigen presentation for adoptive immunotherapy in the post- transplant setting Journal of Clinical Oncology. 25: 3049-3049. DOI: 10.1200/Jco.2007.25.18_Suppl.3049 |
0.492 |
|
| 2007 |
Zakrzewski JL, Suh D, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Lu SX, Cabrera-Perez J, Rizzuto G, Sant’Angelo DB, van den Brink MR, Markley JC, Riviere I, ... Sadelain M, et al. Targeted ‘Off-the-Shelf’ Tumor Immunotherapy Using Allogeneic T-Cell Precursors. Blood. 110: 579-579. DOI: 10.1182/Blood.V110.11.579.579 |
0.544 |
|
| 2007 |
Lee J, Nikhamin Y, Imperato G, Cohen A, Sadelain M, Brentjens R. Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy. Blood. 110: 2754-2754. DOI: 10.1182/Blood.V110.11.2754.2754 |
0.53 |
|
| 2007 |
Lisowski L, Sadelain M. The Importance of the Human β-Globin Locus Control Region HS1 and HS4 Elements for Therapeutic β-Globin Gene Expression in β-Thalassemic Mice. Blood. 110: 272-272. DOI: 10.1182/Blood.V110.11.272.272 |
0.344 |
|
| 2007 |
Hasan A, Kollen WJ, Selvakumar A, Trivedi D, Sadelain M, O’Reilly RJ. A Panel of Artificial Antigen-Presenting Cells (AAPC) Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Subdominant and Dominant Viral Epitopes for Adoptive Therapy. Blood. 110: 2589-2589. DOI: 10.1182/Blood.V110.11.2589.2589 |
0.477 |
|
| 2007 |
Papapetrou EP, Kovalovsky D, Beloeil L, Sant’Angelo D, Sadelain M. microRNA-Mediated Gene Regulation Effectively Restricts In Vivo Transgene Expression in Hematopoietic Stem Cell Progeny. Blood. 110: 193-193. DOI: 10.1182/Blood.V110.11.193.193 |
0.414 |
|
| 2007 |
Sadelain M, Samakoglu S, Chang A, Lisowski L. The expanding application of lentivirus-mediated erythroid-specific gene therapy Blood Cells, Molecules, and Diseases. 38: 176-177. DOI: 10.1016/J.Bcmd.2006.10.127 |
0.319 |
|
| 2006 |
Chang AH, Stephan MT, Sadelain M. Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nature Biotechnology. 24: 1017-21. PMID 16845377 DOI: 10.1038/Nbt1227 |
0.449 |
|
| 2006 |
Budak-Alpdogan T, Przybylowski M, Gonen M, Sadelain M, Bertino J, Rivière I. Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. Human Gene Therapy. 17: 780-94. PMID 16839276 DOI: 10.1089/Hum.2006.17.780 |
0.421 |
|
| 2006 |
Zanzonico P, Koehne G, Gallardo HF, Doubrovin M, Doubrovina E, Finn R, Blasberg RG, Riviere I, O'Reilly RJ, Sadelain M, Larson SM. [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. European Journal of Nuclear Medicine and Molecular Imaging. 33: 988-97. PMID 16607546 DOI: 10.1007/S00259-005-0057-3 |
0.608 |
|
| 2006 |
Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Current Opinion in Hematology. 13: 142-8. PMID 16567956 DOI: 10.1097/01.Moh.0000219658.57915.D4 |
0.402 |
|
| 2006 |
Lyddane C, Gajewska BU, Santos E, King PD, Furtado GC, Sadelain M. Cutting Edge: CD28 controls dominant regulatory T cell activity during active immunization. Journal of Immunology (Baltimore, Md. : 1950). 176: 3306-10. PMID 16517696 DOI: 10.4049/Jimmunol.176.6.3306 |
0.439 |
|
| 2006 |
Kang EM, Hsieh MM, Metzger M, Krouse A, Donahue RE, Sadelain M, Tisdale JF. Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Experimental Hematology. 34: 132-9. PMID 16459181 DOI: 10.1016/J.Exphem.2005.10.010 |
0.334 |
|
| 2006 |
Yuan J, Latouche JB, Hodges J, Houghton AN, Heller G, Sadelain M, Riviere I, Young JW. Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner. Journal of Immunology (Baltimore, Md. : 1950). 176: 2357-65. PMID 16455993 DOI: 10.4049/Jimmunol.176.4.2357 |
0.435 |
|
| 2006 |
Samakoglu S, Lisowski L, Budak-Alpdogan T, Usachenko Y, Acuto S, Di Marzo R, Maggio A, Zhu P, Tisdale JF, Rivière I, Sadelain M. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nature Biotechnology. 24: 89-94. PMID 16378095 DOI: 10.1038/Nbt1176 |
0.441 |
|
| 2006 |
Przybylowski M, Hakakha A, Stefanski J, Hodges J, Sadelain M, Rivière I. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Therapy. 13: 95-100. PMID 16177816 DOI: 10.1038/Sj.Gt.3302648 |
0.387 |
|
| 2006 |
Brentjens RJ, Santos E, Yeh R, La Perle K, Toledo-Crow R, Nikhamin Y, Punzalan B, Entenberg D, Aranda I, Punzalan B, Larson S, Sadelain M. Sensitive In Vivo Detection of Primary T Cells Expressing Membrane-Anchored Gaussia Luciferase for the Study of Adoptive T Cell Immunotherapy in Murine Models of Malignancy. Blood. 108: 3685-3685. DOI: 10.1182/Blood.V108.11.3685.3685 |
0.524 |
|
| 2006 |
Hasan AN, Kollen WJ, Trivedi D, Selvakumar A, Sadelain M, O’Reilly RJ. A Panel of Artificial Antigen Presenting Cells (AAPC) Permits Immediate Sensitization and Rapid Generation of Virus-Specific T-Cells of Desired HLA Restriction for Adoptive Immunotherapy. Blood. 108: 3268-3268. DOI: 10.1182/Blood.V108.11.3268.3268 |
0.482 |
|
| 2006 |
Dobrenkov K, Dabrowska M, Shenker L, Vider E, Gunset G, Sadelain M, Ponomarev V. 763. Multimodality Imaging of Genetically Modified Lymphocytes In Vivo Molecular Therapy. 13: S295. DOI: 10.1016/J.Ymthe.2006.08.848 |
0.424 |
|
| 2006 |
Stefanski J, Borquez-Ojeda O, Budak-Alpdogan T, Kendle R, Przybylowski M, Hollyman D, Sadelain M, Rivière I. 313. Cell Type Specific Media Optimization for Clinical Retroviral Transduction Protocols Molecular Therapy. 13: S119-S120. DOI: 10.1016/J.Ymthe.2006.08.369 |
0.458 |
|
| 2006 |
Zhong X, Matsushita M, Saudemont A, Santos E, Sadelain M. 269. Integrated CD28 and 4-1BB Signals Strongly Potentiate CD8+ T Cell Mediated radication of Metastatic Prostate Cancer Molecular Therapy. 13: S103. DOI: 10.1016/J.Ymthe.2006.08.323 |
0.466 |
|
| 2006 |
Stefanski J, Brentjens R, Hollyman D, Bonyhadi M, Sadelain M, Rivière I. 268. CD19-Targeted Normal and CLL Patient T Cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo Molecular Therapy. 13: S102. DOI: 10.1016/J.Ymthe.2006.08.322 |
0.522 |
|
| 2006 |
Chang AH, Lisowski L, Sadelain M. 1055. High Levels of Human Factor IX Expression in Hemophilia B Mice after Adult Stem Cell-Based Gene Therapy Combined with Non-Myeloablative Conditioning Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.1151 |
0.452 |
|
| 2005 |
Sadelain M, Lisowski L, Samakoglu S, Rivella S, May C, Riviere I. Progress toward the genetic treatment of the beta-thalassemias. Annals of the New York Academy of Sciences. 1054: 78-91. PMID 16339654 DOI: 10.1196/Annals.1345.010 |
0.398 |
|
| 2005 |
Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, ... ... Sadelain M, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Research. 65: 9080-8. PMID 16204083 DOI: 10.1158/0008-5472.Can-05-0436 |
0.466 |
|
| 2005 |
Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells Cancer Research. 65: 5417-5427. PMID 15958591 DOI: 10.1158/0008-5472.Can-04-2991 |
0.445 |
|
| 2005 |
Stolzer AL, Sadelain M, Sant'Angelo DB. Fulminant experimental autoimmune encephalomyelitis induced by retrovirally mediated TCR gene transfer European Journal of Immunology. 35: 1822-1830. PMID 15909313 DOI: 10.1002/Eji.200526123 |
0.485 |
|
| 2005 |
Tabar V, Panagiotakos G, Greenberg ED, Chan BK, Sadelain M, Gutin PH, Studer L. Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nature Biotechnology. 23: 601-6. PMID 15852001 DOI: 10.1038/Nbt1088 |
0.396 |
|
| 2005 |
Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, Heston WDW, Houghton AN, Scher HI. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination International Journal of Cancer. 116: 415-421. PMID 15800947 DOI: 10.1002/Ijc.21014 |
0.327 |
|
| 2005 |
Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, Polycarpe D, Sadelain M, Larson SM. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 1933-8. PMID 15671173 DOI: 10.1073/Pnas.0401851102 |
0.317 |
|
| 2005 |
Yuan J, Latouche JB, Reagan JL, Heller G, Riviere I, Sadelain M, Young JW. Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses. Journal of Immunology (Baltimore, Md. : 1950). 174: 758-66. PMID 15634896 DOI: 10.4049/Jimmunol.174.2.758 |
0.48 |
|
| 2005 |
Kollen WJ, Trivedi D, Stephan M, Sadelain M, O’Reilly RJ. Generation of CMV-Specific T-Lymphocytes for Adoptive Immunotherapy: A Comparison of Artificial Antigen-Presenting Cells and Autologous Dendritic Cells Pulsed with CMV-pp65 Protein-Spanning Pentadecapeptide Pools. Blood. 106: 5546-5546. DOI: 10.1182/Blood.V106.11.5546.5546 |
0.423 |
|
| 2005 |
Trivedi D, Kollen WJ, Barnett L, Sadelain M, O’Reilly RJ. Artificial Antigen-Presenting Cells Permit Selective In Vitro Generation of CMV-Specific T-Cells of Desired HLA Allelic Restriction for Adoptive Immunotherapy in Recipients of HLA Disparate Allografts. Blood. 106: 1298-1298. DOI: 10.1182/Blood.V106.11.1298.1298 |
0.452 |
|
| 2005 |
Samakoglu S, Usachenko Y, Budak-Alpdogan T, Acuto S, DiMarzo R, Maggio A, Tisdale J, Riviere I, Sadelain M. Genetic Correction of Sickle Cell Disease by Co-Regulated γ-Globin Transgene Expression and ßS Interference. Blood. 106: 1280-1280. DOI: 10.1182/Blood.V106.11.1280.1280 |
0.414 |
|
| 2005 |
Brentjens RJ, Nikhamin Y, Matsushita M, Sadelain M. 799. In Vitro and In Vivo Characterization of |[ldquo]|Second-Generation|[rdquo]| Co-Stimulatory Chimeric Antigen Receptors (CARs) Targeting the CD19 Antigen Present on B Cell Malignancies Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.336 |
0.492 |
|
| 2005 |
Stefanski J, Brentjens RJ, Bonyhadi ML, Sadelain M, Rivière I. 707. Transduction and Expansion of T Lymphocytes Genetically Engineered To Target the CD19 Antigen for the Treatment of CLL Using Xcyte|[trade]| Dynabeads|[reg]| Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.247 |
0.533 |
|
| 2005 |
Chang AH, Stephan M, Sadelain M. 604. Long-Term, Erythroid-Specific Expression of Human Factor IX in Hemophilic Mice Engrafted with Lentiviral Vector-Transduced Hematopoietic Stem Cells Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.144 |
0.451 |
|
| 2005 |
Yuan J, Kendle R, Hodges J, Sadelain M, Young JW, Riviere I. 277. Large-Scale Generation of Genetically Modified Human CD34+ Progenitor Cell-Derived Langerhans Cells Using a Closed Culture System Suitable for Clinical Immunotherapy Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.280 |
0.499 |
|
| 2005 |
Lisowski L, Rivella S, Sadelain M. 4. Optimization of Globin Lentiviral Vector Design for the Treatment of |[beta]|-Thalassemia Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.007 |
0.332 |
|
| 2004 |
Sadelain M, Rivella S, Lisowski L, Samakoglu S, Rivière I. Globin gene transfer for treatment of the β-thalassemias and sickle cell disease Best Practice and Research: Clinical Haematology. 17: 517-534. PMID 15498721 DOI: 10.1016/J.Beha.2004.08.002 |
0.434 |
|
| 2004 |
Brentjens RJ, Sadelain M. Somatic Cell Engineering and the Immunotherapy of Leukemias and Lymphomas Advances in Pharmacology. 51: 347-370. PMID 15464917 DOI: 10.1016/S1054-3589(04)51015-3 |
0.359 |
|
| 2004 |
Vyas YM, Maniar H, Lyddane CE, Sadelain M, Dupont B. Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals Journal of Immunology. 173: 1571-1578. PMID 15265884 DOI: 10.4049/Jimmunol.173.3.1571 |
0.342 |
|
| 2004 |
Rivière I, Sadelain M, Brentjens RJ. Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes Current Hematology Reports. 3: 290-297. PMID 15217559 |
0.359 |
|
| 2004 |
Sadelain M. Globin gene transfer as a potential treatment for the β-thalassaemias and sickle cell disease Vox Sanguinis, Supplement. 87: S235-S242. PMID 15209924 DOI: 10.1111/J.1741-6892.2004.00495.X |
0.332 |
|
| 2004 |
Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 22: 1700-8. PMID 15068853 DOI: 10.1016/J.Vaccine.2003.10.048 |
0.372 |
|
| 2004 |
Kim JV, Latouche JB, Rivière I, Sadelain M. The ABCs of artificial antigen presentation. Nature Biotechnology. 22: 403-10. PMID 15060556 DOI: 10.1038/Nbt955 |
0.489 |
|
| 2004 |
Sadelain M. Insertional oncogenesis in gene therapy: How much of a risk? Gene Therapy. 11: 569-573. PMID 15029226 DOI: 10.1038/Sj.Gt.3302243 |
0.382 |
|
| 2004 |
Rivella S, Lisowski L, Sadelain M. Globin gene transfer: A paradigm for transgene regulation and vector safety Gene Therapy and Regulation. 2: 149-175. DOI: 10.1163/156855803322664637 |
0.418 |
|
| 2004 |
Yuan J, Latouche J, Hodges J, Heller G, Riviere I, Sadelain M, Young JW. 555. Langerhans cells modified by gene transfer of full length CMV pp65 are more potent inducers of cytolytic T lymphocytes in a CD4-dependent manner than either CMV p495 gene-modified or p495 peptide-pulsed langerhans cells Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.482 |
0.419 |
|
| 2004 |
Chang AH, Lisowski L, Stephan M, Rivière I, Sadelain M. 72. Position and Copy Number Dependence of the Central Polypurine Tract (cPPT) Function in Simple and Complex Lentiviral Vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.007 |
0.372 |
|
| 2003 |
Doubrovin M, Ponomarev V, Serganova I, Soghomonian S, Myagawa T, Beresten T, Ageyeva L, Sadelain M, Koutcher J, Blasberg RG, Gelovani Tjuvajev JG. Development of a new reporter gene system-dsRed/Xanthine phosphoribosyltransferase-xanthine for molecular imaging of processes behind the intact blood-brain barrier Molecular Imaging. 2: 93-112. PMID 12964307 DOI: 10.1162/153535003322331984 |
0.318 |
|
| 2003 |
Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviére I, Blau CA, Richard RE, Sorrentino B, Nolta J, Malech H, Brenner M, Cornetta K, et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 8: 180-7. PMID 12907140 DOI: 10.1016/S1525-0016(03)00212-0 |
0.399 |
|
| 2003 |
Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nature Reviews. Cancer. 3: 477-88. PMID 12835668 DOI: 10.1038/Nrc1122 |
0.339 |
|
| 2003 |
Papanicolaou GA, Latouche JB, Tan C, Dupont J, Stiles J, Pamer EG, Sadelain M. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele Blood. 102: 2498-2505. PMID 12805061 DOI: 10.1182/Blood-2003-02-0345 |
0.426 |
|
| 2003 |
Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, ... ... Sadelain M, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes Nature Biotechnology. 21: 405-413. PMID 12652311 DOI: 10.1038/Nbt805 |
0.619 |
|
| 2003 |
Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Rivière I, Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nature Medicine. 9: 279-286. PMID 12579196 DOI: 10.1038/Nm827 |
0.477 |
|
| 2003 |
Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes Nature Reviews Cancer. 3: 35-45. PMID 12509765 DOI: 10.1038/Nrc971 |
0.444 |
|
| 2003 |
Rivella S, May C, Chadburn A, Rivière I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer Blood. 101: 2932-2939. PMID 12480689 DOI: 10.1182/Blood-2002-10-3305 |
0.349 |
|
| 2003 |
Kohn DB, Sadelain M, Glorioso JC. Correction: Occurrence of leukaemia following gene therapy of X-linked SCID Nature Reviews Cancer. 3: 883-883. DOI: 10.1038/Nrc1236 |
0.358 |
|
| 2003 |
Doubrovina E, Latouche J, Lee S, Raab-Traub N, Pamer E, Sadelain M, O'Reilly R. 27 A novel strategy for generating LMPI specific T cells utilizing artificial antigen presenting cells Biology of Blood and Marrow Transplantation. 9: 71. DOI: 10.1016/S1083-8791(03)80028-9 |
0.486 |
|
| 2002 |
MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, Moore MA. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene. 21: 4200-11. PMID 12082607 DOI: 10.1038/Sj.Onc.1205425 |
0.363 |
|
| 2002 |
Sadelain M. Globin gene transfer for the treatment of severe hemoglobinopathies: A paradigm for cell-based gene therapy Journal of Gene Medicine. 4: 113-121. PMID 11933212 DOI: 10.1002/Jgm.266 |
0.444 |
|
| 2002 |
May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene Blood. 99: 1902-1908. PMID 11877258 DOI: 10.1182/Blood.V99.6.1902 |
0.363 |
|
| 2002 |
De Angioletti M, Rovira A, Sadelain M, Luzzatto L, Notaro R. Frequency of missense mutations in the coding region of a eukaryotic gene transferred by retroviral vectors Journal of Virology. 76: 1991-1994. PMID 11799194 DOI: 10.1128/Jvi.76.4.1991-1994.2002 |
0.344 |
|
| 2002 |
Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor Nature Biotechnology. 20: 70-75. PMID 11753365 DOI: 10.1038/Nbt0102-70 |
0.5 |
|
| 2001 |
Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, Larson S, Blasberg R, Sadelain M, Tjuvajev JG. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo Neoplasia. 3: 480-488. PMID 11774030 DOI: 10.1038/Sj.Neo.7900204 |
0.46 |
|
| 2001 |
May C, Sadelain M. A promising genetic approach to the treatment of β-thalassemia Trends in Cardiovascular Medicine. 11: 276-280. PMID 11709281 DOI: 10.1016/S1050-1738(01)00125-6 |
0.44 |
|
| 2001 |
Tasch J, Gong M, Sadelain M, Heston WDW. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy? Critical Reviews in Immunology. 21: 249-261. PMID 11642607 DOI: 10.1615/Critrevimmunol.V21.I1-3.160 |
0.303 |
|
| 2001 |
Tisdale J, Sadelain M. Toward gene therapy for disorders of globin synthesis Seminars in Hematology. 38: 382-392. PMID 11605174 DOI: 10.1016/S0037-1963(01)90033-2 |
0.434 |
|
| 2001 |
Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, Tjuvajev JG. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo Proceedings of the National Academy of Sciences of the United States of America. 98: 9300-9305. PMID 11481488 DOI: 10.1073/Pnas.161091198 |
0.302 |
|
| 2001 |
De Angioletti M, Rovira A, Notaro R, Camacho Vanegas O, Sadelain M, Luzzatto L. Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter Gene. 267: 221-231. PMID 11313149 DOI: 10.1016/S0378-1119(01)00394-8 |
0.368 |
|
| 2001 |
Takebe N, Zhao SC, Adhikari D, Mineishi S, Sadelain M, Hilton J, Colvin M, Banerjee D, Bertino JR. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 88-96. PMID 11162315 DOI: 10.1006/Mthe.2000.0236 |
0.347 |
|
| 2001 |
Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes Blood. 97: 114-121. PMID 11133750 DOI: 10.1182/Blood.V97.1.114 |
0.418 |
|
| 2001 |
Marti F, Krause A, Post NH, Lyddane C, Dupont B, Sadelain M, King PD. Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6 Journal of Immunology. 166: 197-206. PMID 11123293 DOI: 10.4049/Jimmunol.166.1.197 |
0.335 |
|
| 2001 |
Sadelain M, Blasberg RG. Imaging transgene expression for gene therapy Journal of Pharmacy Practice. 14: 376-382. DOI: 10.1002/J.1552-4604.1999.Tb05936.X |
0.31 |
|
| 2000 |
Rovira A, De Angioletti M, Camacho-Vanegas O, Liu D, Rosti V, Gallardo HF, Notaro R, Sadelain M, Luzzatto L. Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer Blood. 96: 4111-4117. PMID 11110681 DOI: 10.1182/Blood.V96.13.4111.H8004111_4111_4117 |
0.431 |
|
| 2000 |
Sadelain M, Frassoni F, Rivière I. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells Current Opinion in Hematology. 7: 364-377. PMID 11055510 DOI: 10.1097/00062752-200011000-00008 |
0.451 |
|
| 2000 |
MacKenzie KL, Franco S, May C, Sadelain M, Moore MA. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Experimental Cell Research. 259: 336-50. PMID 10964501 DOI: 10.1006/Excr.2000.4982 |
0.412 |
|
| 2000 |
Riviere I, Gallardo HF, Hagani AB, Sadelain M. Retroviral-mediated gene transfer in primary murine and human T-lymphocytes Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology. 15: 133-142. PMID 10949826 DOI: 10.1385/Mb:15:2:133 |
0.491 |
|
| 2000 |
Chad M, Rivella S, Callegari J, Heller G, Gaensler KML, Luzzatto L, Sadelain M. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin Nature. 406: 82-86. PMID 10894546 DOI: 10.1038/35017565 |
0.414 |
|
| 2000 |
Koehne G, Gallardo HF, Sadelain M, O'Reilly RJ. Rapid selection of antigen-specific T lymphocytes by retroviral transduction Blood. 96: 109-117. PMID 10891438 DOI: 10.1182/Blood.V96.1.109.013K44_109_117 |
0.626 |
|
| 2000 |
Rivella S, Callegari JA, May C, Tan CW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites Journal of Virology. 74: 4679-4687. PMID 10775605 DOI: 10.1128/Jvi.74.10.4679-4687.2000 |
0.352 |
|
| 2000 |
Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen- presenting cells Nature Biotechnology. 18: 405-409. PMID 10748520 DOI: 10.1038/74455 |
0.436 |
|
| 2000 |
Schnell S, Young JW, Houghton AN, Sadelain M. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 164: 1243-50. PMID 10640737 DOI: 10.4049/Jimmunol.164.3.1243 |
0.374 |
|
| 1999 |
Tjuvajev JG, Joshi A, Callegari J, Lindsley L, Joshi R, Balatoni J, Finn R, Larson SM, Sadelain M, Blasberg RG. A General Approach to the Non-Invasive Imaging of Transgenes Using Cis-Linked Herpes Simplex Virus Thymidine Kinase Neoplasia. 1: 315-320. PMID 10935486 DOI: 10.1038/Sj.Neo.7900053 |
0.342 |
|
| 1999 |
Gong MC, Latouche JB, Krause A, Heston WDW, Bander NH, Sadelain M. Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen Neoplasia. 1: 123-127. PMID 10933046 DOI: 10.1038/Sj.Neo.7900018 |
0.446 |
|
| 1999 |
Hagani AB, Rivière I, Tan C, Krause A, Sadelain M. Activation Conditions Determine Susceptibility of Murine Primary T-lymphocytes to Retroviral Infection Journal of Gene Medicine. 1: 341-351. PMID 10738551 DOI: 10.1002/(Sici)1521-2254(199909/10)1:5<341::Aid-Jgm58>3.0.Co;2-J |
0.468 |
|
| 1999 |
Kim SJ, Sadelain M, Lee JS, Seong RH, Yun YS, Jang YJ, Chung HY. Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line Cancer Immunology Immunotherapy. 47: 257-264. PMID 10022469 DOI: 10.1007/S002620050529 |
0.456 |
|
| 1999 |
Gong MC, Latouche J, Krause A, Heston WDW, Bander NH, Sadelain M. Prostate Cancer Patient T Cells Genetically Targeted To Prostate-Specific Membrane Antigen Specifically And Efficiently Lyse Prostate Cancer Cells The Journal of Urology. 60. DOI: 10.1097/00005392-199904010-00242 |
0.318 |
|
| 1998 |
Scott-Taylor TH, Gansbacher B, Sadelain M. Efficient retroviral infection of human cells utilising an adenoviral vector expressing the ecotropic receptor Advances in Experimental Medicine and Biology. 451: 423-430. PMID 10026906 DOI: 10.1007/978-1-4615-5357-1_65 |
0.427 |
|
| 1998 |
Scott-Taylor TH, Gallardo HF, Gänsbacher B, Sadelain M. Adenovirus facilitated infection of human cells with ecotropic retrovirus Gene Therapy. 5: 621-629. PMID 9797866 DOI: 10.1038/Sj.Gt.3300633 |
0.379 |
|
| 1998 |
Krause A, Guo HF, Latouche JB, Tan C, Cheung NKV, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes Journal of Experimental Medicine. 188: 619-626. PMID 9705944 DOI: 10.1084/Jem.188.4.619 |
0.458 |
|
| 1998 |
Rivella S, Sadelain M. Genetic treatment of severe hemoglobinopathies: The combat against transgene variegation and transgene silencing Seminars in Hematology. 35: 112-125. PMID 9565154 |
0.391 |
|
| 1998 |
Mach N, Lantz CS, Galli SJ, Reznikoff G, Mihm M, Small C, Granstein R, Beissert S, Sadelain M, Mulligan RC, Dranoff G. Involvement of interleukin-3 in delayed-type hypersensitivity. Blood. 91: 778-83. PMID 9446636 DOI: 10.1182/Blood.V91.3.778.778_778_783 |
0.502 |
|
| 1997 |
Sadelain M. Methods for retrovirus-mediated gene transfer into primary T-lymphocytes. Methods in Molecular Medicine. 7: 241-248. PMID 24493431 DOI: 10.1385/0-89603-484-4:241 |
0.447 |
|
| 1997 |
Rivière I, Sadelain M. Methods for the construction of retroviral vectors and the generation of high-titer producers. Methods in Molecular Medicine. 7: 59-78. PMID 24493418 DOI: 10.1385/0-89603-484-4:59 |
0.403 |
|
| 1997 |
Gallardo HF, Tan C, Sadelain M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes Gene Therapy. 4: 1115-1119. PMID 9415319 DOI: 10.1038/Sj.Gt.3300506 |
0.484 |
|
| 1997 |
Szabolcs P, Gallardo HF, Ciocon DH, Sadelain M, Young JW. Retrovirally Transduced Human Dendritic Cells Express a Normal Phenotype and Potent T-Cell Stimulatory Capacity Blood. 90: 2160-2167. DOI: 10.1182/Blood.V90.6.2160.2160_2160_2167 |
0.494 |
|
| 1997 |
Gallardo H, Tan C, Ory D, Sadelain M. Recombinant Retroviruses Pseudotyped With the Vesicular Stomatitis Virus G Glycoprotein Mediate Both Stable Gene Transfer and Pseudotransduction in Human Peripheral Blood Lymphocytes Blood. 90: 952-957. DOI: 10.1182/Blood.V90.3.952.952_952_957 |
0.395 |
|
| 1995 |
Sadelain M, Wang CH, Antoniou M, Grosveld F, Mulligan RC. Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proceedings of the National Academy of Sciences of the United States of America. 92: 6728-32. PMID 7624311 DOI: 10.1073/Pnas.92.15.6728 |
0.545 |
|
| 1994 |
Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 91: 4348-52. PMID 8183911 DOI: 10.1073/Pnas.91.10.4348 |
0.308 |
|
| 1994 |
Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Bachurski CJ, Mark EL, Whitsett JA. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science (New York, N.Y.). 264: 713-6. PMID 8171324 DOI: 10.1126/Science.8171324 |
0.303 |
|
| Show low-probability matches. |